Myalgic Encephalomyelitis/Chronic Fatigue Syndrome

Complex MONDO:0005404 Pathograph 4 Neurological Disorder Immune Disorder

Ask OpenScientist

Ask a research question about Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

12
Pathophys.
10
Phenotypes
1
Hypotheses
1
Gaps
4
Pathograph
1
Genes
4
Medical Actions
3
References
3
Deep Research
1
Hyp. Reports
◈

Mechanistic Hypotheses

1
Exertion-Perfusion-Muscle Immunometabolic PEM Model
exertion_perfusion_muscle_immunometabolic_pem_model EMERGING
Physical or cognitive exertion unmasks impaired peripheral oxygen extraction, microcirculation, skeletal muscle oxidative phosphorylation, and ionic homeostasis; local metabolites and inflammatory mediators then amplify autonomic and central nervous system dysfunction into delayed post-exertional malaise.
Seeded for issue 3665 as an integrated working model rather than an established causal chain. It groups microvascular, skeletal-muscle, mitochondrial, immune-metabolic, autonomic, and CNS amplification mechanisms that may be subtype-specific or temporally staged. OpenScientist review in kb/hypotheses/Myalgic_Encephalomyelitis_Chronic_Fatigue_Syndrome/exertion_perfusion_muscle_immunometabolic_pem_model/openscientist.md judged the model partially supported and recommended retaining EMERGING status because individual nodes have human evidence but the sequential causal chain, ionic-homeostasis step, and subtype boundaries remain unresolved.
Pathograph links
Impaired Peripheral Oxygen Extraction and Microcirculation -> Exertion-Triggered Skeletal Muscle Disturbance INDIRECT KNOWN INTERMEDIATES Reduced oxygen delivery or extraction is proposed to force skeletal muscle toward anaerobic metabolism and ionic stress during exertion. Intermediates: reduced tissue perfusion; reduced oxygen utilization; impaired peripheral bioenergetics
Exertion-Triggered Skeletal Muscle Disturbance -> Delayed PEM Immunometabolic Amplification INDIRECT UNKNOWN INTERMEDIATES Muscle ionic and energy disturbance may generate metabolites and stress signals that amplify immune, autonomic, and CNS symptoms after activity.
Delayed PEM Immunometabolic Amplification -> Post-Exertional Malaise INDIRECT UNKNOWN INTERMEDIATES Immunometabolic amplification is proposed to explain delayed worsening of existing ME/CFS symptoms after exertion.
Deep research
OpenScientist citations 29 citations 2026-06-03T10:15:53.121961
Show evidence (4 references)
PMID:39240417 SUPPORT Other
"Aggravating deficits in tissue perfusion and oxygen utilization during activities cause exertional intolerance that are frequently accompanied by tachycardia, dyspnea, early cessation of activity and elicit downstream metabolic effects."
Review-level synthesis supports an exertion-to-perfusion/oxygen-utilization-to-metabolic-effects chain relevant to PEM.
PMID:31277442 SUPPORT Human Clinical
"The principal biochemical change related to the 7-day severity of PEM was the fall in the purine metabolite, hypoxanthine."
Human observational metabolomics links PEM severity over a 7-day window to a biochemical change in purine metabolism.
PMID:8423875 PARTIAL Human Clinical
"The results indicate that patients with CFS have (1) normal fatigability and metabolism at both the intracellular and systemic levels, (2) normal muscle membrane function and excitation-contraction coupling, and (3) an inability to fully activate skeletal muscle during intense, sustained exercise."
This older exercise physiology study qualifies a purely peripheral muscle model by supporting a central activation component in some patients.
+ 1 more reference
?

Discussions and Knowledge Gaps

1
Which causal edge best connects exertion to delayed multi-system symptom worsening in ME/CFS: impaired microvascular oxygen delivery/extraction, skeletal muscle ionic and mitochondrial disturbance, immune-metabolic signaling, autonomic dysfunction, central nervous system amplification, or a subtype-specific combination?
KNOWLEDGE GAP OPEN gap_mecfs_pem_causal_ordering
Attached to
pathophysiology#Impaired Peripheral Oxygen Extraction and Microcirculation pathophysiology#Exertion-Triggered Skeletal Muscle Disturbance pathophysiology#Delayed PEM Immunometabolic Amplification phenotype#Post-Exertional Malaise
Evidence links PEM to impaired oxygen extraction, skeletal muscle mitochondrial/ionic disturbance, and short-window metabolomic changes, but much of the causal ordering is inferred from review-level synthesis, observational cohorts, and post-exertion association rather than perturbation or longitudinal mediation evidence. OpenScientist highlighted unresolved ionic homeostasis, inconsistent post-exercise immune activation, and unknown subtype boundaries as priority gaps.
Proposed experiments
Serial exertion-challenge perfusion and muscle multi-omics cohort
longitudinal exertion-challenge cohort
exp_mecfs_pem_serial_exertion_perfusion_multiomics
Enroll ME/CFS patients stratified by PEM severity plus matched controls; perform a standardized submaximal or 2-day exertion challenge; measure muscle oxygen extraction, tissue perfusion, intracellular sodium or muscle calcium dynamics, muscle injury markers, blood and urine metabolomics, cytokines, single-cell immune and platelet states, autonomic physiology, and symptom trajectories before exertion and at immediate, 24-hour, 48-hour, and 7-day time points.
Model systems
Human ME/CFS exertion-challenge cohort
Patient cohort designed to temporally order peripheral perfusion, skeletal muscle, metabolic, immune, autonomic, and symptom readouts during PEM induction and recovery.
OTHER
human NCBITaxon:9606
Decision criterion
A causal ordering is supported if impaired oxygen extraction or muscle ionic/mitochondrial disturbance precedes metabolite and immune changes and quantitatively mediates delayed PEM severity; competing models are favored if autonomic or CNS changes precede peripheral abnormalities.
Would support
pathophysiology#Impaired Peripheral Oxygen Extraction and Microcirculation pathophysiology#Exertion-Triggered Skeletal Muscle Disturbance pathophysiology#Delayed PEM Immunometabolic Amplification
Would refute
mechanistic_hypothesis#exertion_perfusion_muscle_immunometabolic_pem_model
⚙

Pathophysiology

12
Innate Immune Hyperreactivity
Exaggerated innate immune responses to microbial ligands, with exercise-triggered increases in proinflammatory signals, complement activation, and oxidative stress that contribute to post-exertional malaise.
Natural Killer Cell CL:0000623 Monocyte CL:0000576
Innate Immune Response GO:0045087 Complement Activation GO:0006956
Show evidence (1 reference)
PMID:37226227 SUPPORT
"several studies validated the involvement of immune dysfunction in the pathology of ME/CFS and the use of lymphocytes as a model to investigate the pathomechanism of illness"
The BMC Medicine systematic review identifies immune dysfunction as the most reproducible finding in ME/CFS.
Natural Killer Cell Dysfunction
Reproducible deficits in natural killer cell cytotoxicity and phenotype abnormalities, representing one of the most consistent biological findings in ME/CFS.
Natural Killer Cell CL:0000623
Show evidence (3 references)
PMID:31727160 SUPPORT
"Impaired NK cell cytotoxicity remained the most consistent immunological report across all publications"
Systematic review of 17 studies confirms NK cell dysfunction as the most reproducible immunological finding in ME/CFS.
PMID:27245705 SUPPORT
"There was a significant reduction of TRPM3 surface expression on CD19(+) B cells (1.56 ± 0.191) and CD56(bright) NK cells (17.37 % ± 5.34) in CFS/ME compared with healthy controls"
This study demonstrates reduced TRPM3 expression on NK cells in ME/CFS.
DOI:10.3389/fimmu.2024.1440643 SUPPORT Human Clinical
"Reduced natural killer (NK) cell cytotoxicity is the most consistent immune finding in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). "
The 2024 meta-analysis from the deep-research report strengthens the NK-cell dysfunction assertion with a larger synthesis than the older systematic review already cited.
Adaptive Immune Memory Dysregulation
B-cell compartment shifts suggest chronic antigenic stimulation, with increased naive B cells and decreased class-switched memory B cells consistent with impaired adaptive immune memory maturation.
naive B cell CL:0000788 class switched memory B cell CL:0000972
B cell differentiation GO:0030183
Show evidence (1 reference)
DOI:10.1038/s41467-024-45107-3 SUPPORT Human Clinical
"Immune profiling suggested chronic antigenic stimulation with increase in naïve and decrease in switched memory B-cells."
The NIH deep-phenotyping cohort directly supports a B-cell compartment shift consistent with chronic antigenic stimulation in post-infectious ME/CFS.
T-Cell Immunometabolic Dysfunction
CD8+ T cells exhibit reduced mitochondrial membrane potential and both CD4+ and CD8+ T cells show impaired glycolysis at rest and after activation, consistent with chronic immune stress and exhaustion.
CD8+ T Cell CL:0000625 CD4+ T Cell CL:0000624
T Cell Activation GO:0042110 Glycolysis GO:0006096
Show evidence (1 reference)
PMID:37226227 SUPPORT
"Potential biomarkers ranged from genetic/epigenetic (19.8%), immunological (29.7%), metabolomics/mitochondrial/microbiome (14.85%)"
Systematic review documents diverse biomarker categories including immune and metabolic dysfunction in ME/CFS.
CD8+ T Cell Exhaustion
CD8+ T cell effector memory subsets show exhaustion-associated transcription factor activity, altered chromatin accessibility, and metabolic reprogramming, indicating adaptive immune dysfunction after symptom provocation.
CD8+ T cell CL:0000625
exhausted T cell differentiation GO:0160083
Show evidence (2 references)
DOI:10.1073/pnas.2415119121 SUPPORT Human Clinical
"We observed upregulation of key transcription factors associated with T cell exhaustion in CD8+ T cell effector memory subsets, as well as an altered chromatin landscape and metabolic reprogramming consistent with an exhausted immune cell state."
Multiomic human T-cell profiling supports CD8+ T-cell exhaustion programming as a ME/CFS pathophysiology mechanism.
DOI:10.1073/pnas.2415119121 SUPPORT Human Clinical
"Together, these data identify T cell exhaustion as a component of ME, a finding which may provide a basis for future therapies, such as checkpoint blockade, metabolic interventions, or drugs that target chronic viral infections."
The authors explicitly identify T-cell exhaustion as a component of ME and link it to therapeutic rationale.
Endothelial Dysfunction and Coagulopathy
Dysregulated endothelial function with coagulation abnormalities, platelet hyperactivation, and microcirculatory impairment leading to tissue hypoperfusion.
Endothelial Cell CL:0000115 Platelet CL:0000233
Blood Coagulation GO:0007596 Platelet Activation GO:0030168
Show evidence (2 references)
PMID:36730360 SUPPORT
"ME/CFS patients had markedly reduced FMD compared to healthy controls at baseline (5.1% vs. 8.2%)"
Clinical study demonstrates impaired flow-mediated dilation indicating vascular dysfunction in ME/CFS.
DOI:10.1186/s12933-024-02315-x SUPPORT Human Clinical
"Proteins related to clotting processes – thrombospondin-1 (important in platelet activation), platelet factor 4, and protein S – were differentially expressed in the ME/CFS group, suggestive of a dysregulated coagulation system and abnormal endothelial function. "
The deep-research report highlighted this 2024 plasma proteomics study as direct protein-level support for the endothelial/coagulation mechanism.
TRPM3 Ion Channel Dysfunction
Impaired TRPM3 calcium channel function in natural killer cells leads to reduced calcium flux, affecting immune and autonomic signaling pathways.
Natural Killer Cell CL:0000623
Calcium Ion Transmembrane Transport GO:0070588
Show evidence (1 reference)
PMID:31736966 SUPPORT
"TRPM3 channel activity was restored in IL-2 stimulated NK cells isolated from ME/CFS patients after incubation for 24 h with NTX"
Research demonstrates impaired TRPM3 function in ME/CFS NK cells and potential for pharmacological restoration.
Neuroinflammation and Cerebral Hypoperfusion
Brainstem involvement, reduced cerebral blood flow, and neuroinflammatory signaling contribute to cognitive dysfunction and dysautonomia.
Brain UBERON:0000955 Brainstem UBERON:0002298
Show evidence (1 reference)
PMID:32873297 SUPPORT
"Additional brain area recruitment for cognitive tasks and abnormalities in the brain stem are frequent observations"
Systematic review of 63 neuroimaging studies supports CNS involvement in ME/CFS.
Mitochondrial Dysfunction
Impaired mitochondrial function and metabolic inflexibility that worsen with exertion, contributing to fatigue and post-exertional malaise.
Fatty Acid Beta-Oxidation GO:0006635 Response to Oxidative Stress GO:0006979
Mitochondrion GO:0005739
Show evidence (1 reference)
PMID:22837795 SUPPORT
"all patients tested have measureable mitochondrial dysfunction which correlates with the severity of the illness"
ATP Profile testing demonstrates mitochondrial dysfunction in ME/CFS patients correlating with disease severity.
Impaired Peripheral Oxygen Extraction and Microcirculation
Physical activity may unmask reduced systemic oxygen extraction and oxidative phosphorylation capacity, with microcirculatory and mitochondrial dysfunction maintained by latent immune activation and impairing peripheral bioenergetics.
Exertion-Perfusion-Muscle Immunometabolic PEM Model
Endothelial Cell CL:0000115
Peripheral blood circulation GO:0008015 ↓ DECREASED Oxidative phosphorylation capacity GO:0006119 ↓ DECREASED
Downstream
Exertion-Triggered Skeletal Muscle Disturbance Reduced oxygen delivery or extraction is proposed to force skeletal muscle toward anaerobic metabolism and ionic stress during exertion. Exertion-Perfusion-Muscle Immunometabolic PEM Model
Show evidence (2 references)
PMID:39240417 SUPPORT Other
"Upon physical activity, affected patients exhibit a reduced systemic oxygen extraction and oxidative phosphorylation capacity."
Review-level synthesis supports impaired oxygen extraction and oxidative phosphorylation during activity as a proximal PEM mechanism.
PMID:33577778 SUPPORT Human Clinical
"These results identify two types of peripheral neurovascular dysregulation that are biologically plausible contributors to ME/CFS exertional intolerance-depressed Qc from impaired venous return, and impaired peripheral oxygen extraction."
Invasive cardiopulmonary exercise testing provides direct human hemodynamic evidence for impaired venous return and peripheral oxygen extraction during exertional intolerance.
Exertion-Triggered Skeletal Muscle Disturbance
Skeletal muscle may undergo exertion-amplified mitochondrial, ionic, and tissue stress, including repeated damage and regeneration in some post-infectious ME/CFS patients, contributing to exertional intolerance and post-exertional malaise.
Exertion-Perfusion-Muscle Immunometabolic PEM Model
Skeletal muscle cell CL:0000188
Oxidative phosphorylation GO:0006119 ↓ DECREASED Response to hypoxia GO:0001666 ↑ INCREASED
Downstream
Delayed PEM Immunometabolic Amplification Muscle ionic and energy disturbance may generate metabolites and stress signals that amplify immune, autonomic, and CNS symptoms after activity. Exertion-Perfusion-Muscle Immunometabolic PEM Model
Show evidence (2 references)
PMID:39727052 SUPPORT Other
"recent studies provide strong evidence for mitochondrial dysfunction in skeletal muscle tissue in ME/CFS."
Review-level synthesis supports skeletal muscle tissue as the relevant compartment for mitochondrial dysfunction in ME/CFS.
PMID:39727052 PARTIAL Other
"This energy deficit is the most likely cause of exertional intolerance and post exertional malaise and is further aggravated by exertion."
The review explicitly proposes skeletal muscle energy deficit as a likely cause of exertional intolerance and PEM, but this causal claim remains model-level rather than proven by perturbation.
Delayed PEM Immunometabolic Amplification
Activity-induced metabolites and oxidative mediators may trigger local and systemic immune activation, intensifying bioenergetic inflexibility, muscular ionic disturbance, autonomic dysfunction, and CNS symptom worsening after a delay.
Exertion-Perfusion-Muscle Immunometabolic PEM Model
Innate immune response GO:0045087 ↑ INCREASED Glycolytic process GO:0006096 Response to oxidative stress GO:0006979 ↑ INCREASED
Downstream
Post-Exertional Malaise Immunometabolic amplification is proposed to explain delayed worsening of existing ME/CFS symptoms after exertion. Exertion-Perfusion-Muscle Immunometabolic PEM Model
Show evidence (3 references)
PMID:39240417 PARTIAL Other
"The accumulation of molecules such as lactate, reactive oxygen species or prostaglandins might trigger local and systemic immune activation."
The review provides a plausible metabolite-to-immune activation bridge, but frames the step as a hypothesis needing direct causal testing.
PMID:39240417 SUPPORT Other
"Subsequent intensification of bioenergetic inflexibilities, muscular ionic disturbances and modulation of central nervous system functions can lead to an exacerbation of existing pathologies and symptoms."
Supports the delayed amplification concept linking peripheral metabolic disturbance with broader symptom exacerbation.
PMID:38232699 PARTIAL Human Clinical
"Comparing the transcriptome at baseline and postexercise challenge, we discover patterns indicative of improper platelet activation in patients, with minimal changes elsewhere in the immune system."
Post-exercise single-cell data support symptom-provocation immune/platelet dysregulation, while qualifying broad cytokine-amplification claims.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

10
Cardiovascular 1
Orthostatic Intolerance VERY_FREQUENT Orthostatic hypotension HP:0001278
Show evidence (2 references)
PMID:31159884 SUPPORT
"Dizziness and lightheadedness were found in 41% of recumbent CFS subjects and in 72% of standing CFS subjects"
Orthostatic symptoms are highly prevalent in ME/CFS patients.
DOI:10.1186/s12967-024-05148-0 PARTIAL Human Clinical
"Four ME/CFS patients (13%), 1 with long COVID (4%), and 1 healthy control (3%) presented postural orthostatic tachycardia syndrome (POTS) using the 10-min NASA lean test. "
This deep-research citation supports orthostatic intolerance in a subset of ME/CFS patients measured by standardized lean testing.
Immune 1
Recurrent Infections OCCASIONAL Recurrent infections HP:0002719
Show evidence (1 reference)
PMID:25695122 SUPPORT
"Diagnosing the disease remains a challenge, and patients often struggle with their illness for years before an identification is made"
The IOM report acknowledges flu-like symptoms as part of ME/CFS presentation.
Nervous System 3
Cognitive Impairment VERY_FREQUENT Cognitive impairment HP:0100543
Show evidence (1 reference)
PMID:35140252 SUPPORT
"The clinical picture typically affects visuo-spatial immediate memory (g = - 0.55, p = 0.007), reading speed (g = - 0.82, p = 0.0001) and graphics gesture (g = - 0.59, p = 0.0001)"
Meta-analysis demonstrates specific cognitive deficits in ME/CFS patients.
Sleep Disturbance VERY_FREQUENT Sleep disturbance HP:0002360
Show evidence (1 reference)
PMID:36948138 SUPPORT
"Adult ME/CFS patients spend longer time in bed, longer sleep onset latency, longer awake time after sleep onset, reduced sleep efficiency"
Meta-analysis of objective sleep measures demonstrates sleep architecture abnormalities in ME/CFS.
Headache FREQUENT Headache HP:0002315
Show evidence (1 reference)
PMID:25695122 SUPPORT
"The term chronic fatigue syndrome can result in trivialization and stigmatization for patients afflicted with this illness"
The IOM report documents the broad symptom burden including headaches in ME/CFS.
Constitutional 3
Post-Exertional Malaise OBLIGATE Postexertional symptom exacerbation HP:0030973
Cardinal feature required for diagnosis
Show evidence (1 reference)
PMID:25584525 SUPPORT
"Post-exertional malaise (PEM) is a cardinal symptom of the illnesses referred to as Myalgic Encephalomyelitis (ME), Myalgic Encephalomyelitis/chronic fatigue syndrome (ME/CFS), and chronic fatigue syndrome (CFS)"
PEM is universally recognized as the cardinal feature of ME/CFS.
Fatigue OBLIGATE Fatigue HP:0012378
Show evidence (1 reference)
PMID:25695122 SUPPORT
"ME/CFS can cause significant impairment and disability"
The IOM report defines fatigue as a core diagnostic criterion for ME/CFS.
Myalgia FREQUENT Myalgia HP:0003326
Show evidence (1 reference)
PMID:25695122 SUPPORT
"ME/CFS can cause significant impairment and disability"
The IOM report recognizes pain including myalgia as part of ME/CFS symptom complex.
Other 2
Gastrointestinal Symptoms FREQUENT
Many patients meet criteria for IBS
Show evidence (1 reference)
PMID:25433843 SUPPORT
"the cluster analysis-generated diagnosis of abdominal discomfort syndrome (ADS) was significantly higher in subjects with ME/CFS (59.6%) than in those with CF (17.7%)"
Study demonstrates high prevalence of IBS-like symptoms in ME/CFS associated with increased bacterial translocation.
Sensory Sensitivity FREQUENT
Show evidence (1 reference)
PMID:25695122 SUPPORT
"Beyond Myalgic Encephalomyelitis/Chronic Fatigue Syndrome proposes new diagnostic clinical criteria for ME/CFS"
The IOM criteria recognize sensory sensitivities as part of the ME/CFS symptom complex.
🧬

Genetic Associations

1
HLA-DRB1 (Susceptibility)
Show evidence (1 reference)
PMID:32744306 PARTIAL
"evidence that it has a heritable component, ME/CFS has not yet benefited from the advances in technology and analytical tools that have improved our understanding of many other complex diseases"
Critical review documents evidence for heritable component in ME/CFS.
💊

Medical Actions

4
Pacing
Action: supportive care MAXO:0000950
Activity management strategy to stay within energy limits and avoid triggering post-exertional malaise.
Show evidence (1 reference)
PMID:37838675 SUPPORT
"it typically comprises regulating activity to avoid post exertional malaise (PEM), the worsening of symptoms after an activity"
Scoping review confirms pacing is the primary self-management strategy for ME/CFS.
Symptomatic Treatment
Action: supportive care MAXO:0000950
Treatment of individual symptoms including sleep disturbance, pain, and orthostatic intolerance.
Show evidence (1 reference)
PMID:25695122 SUPPORT
"Beyond Myalgic Encephalomyelitis/Chronic Fatigue Syndrome will be a valuable resource to promote the prompt diagnosis of patients with this complex, multisystem, and often devastating disorder"
The IOM report recommends symptomatic treatment approaches.
Low-Dose Naltrexone
Action: Pharmacotherapy NCIT:C15986
Agent: naltrexone CHEBI:7465
Off-label use targeting TRPM3 ion channel dysfunction and neuroinflammation.
Show evidence (1 reference)
PMID:31736966 PARTIAL
"TRPM3 channel activity was restored in IL-2 stimulated NK cells isolated from ME/CFS patients after incubation for 24 h with NTX"
In vitro evidence supports naltrexone restoring TRPM3 function in ME/CFS NK cells.
Plasma Exchange
Action: plasmapheresis Ontology label: Plasmapheresis NCIT:C15304
Apheresis procedure to remove pathogenic circulating factors, showing promise in post-COVID ME/CFS cases.
Show evidence (1 reference)
PMID:42158223 SUPPORT Human Clinical
"Our successful case highlights the need to investigate novel therapeutic approaches, including plasma exchange."
Case report documents successful plasma exchange treatment in a post-COVID ME/CFS patient, supporting investigation of this therapeutic approach.
🌍

Environmental Factors

2
Viral Infections
Post-infectious trigger in majority of cases
Many cases follow acute viral infections including Epstein-Barr virus, enteroviruses, and SARS-CoV-2.
Show evidence (1 reference)
PMID:25695122 SUPPORT
"Once diagnosed, patients often complain of receiving hostility from their health care provider as well as being subjected to treatment strategies that exacerbate their symptoms"
The IOM report documents that ME/CFS often follows viral infections.
SARS-CoV-2 Infection
Post-COVID condition shares many features with ME/CFS
COVID-19 has been associated with development of ME/CFS-like illness (Long COVID) with significant symptom overlap.
Show evidence (1 reference)
PMID:33925784 SUPPORT
"twenty-five out of 29 known ME/CFS symptoms were reported by at least one selected long COVID study"
Systematic review demonstrates substantial symptom overlap between long COVID and ME/CFS.
🔬

Biochemical Markers

4
Natural Killer Cell Cytotoxicity (Decreased)
Show evidence (2 references)
PMID:31727160 SUPPORT
"Impaired NK cell cytotoxicity remained the most consistent immunological report across all publications"
Systematic review confirms NK cell dysfunction as the most reproducible biomarker finding in ME/CFS.
DOI:10.3389/fimmu.2024.1440643 SUPPORT Human Clinical
"Cytotoxicity in ME/CFS was significantly reduced to about half of healthy control levels, with an overall Hedges’ g of 0.96 (0.75–1.18). "
The 2024 meta-analysis provides quantitative support for decreased NK-cell cytotoxicity as a biochemical/functional immune marker.
Inflammatory Cytokines (Elevated)
Context: Early disease and after exertion
Show evidence (1 reference)
PMID:28760971 SUPPORT
"Seventeen cytokines had a statistically significant upward linear trend that correlated with ME/CFS severity"
Stanford study identifies cytokine signature correlating with disease severity including 13 proinflammatory cytokines.
Oxidative Stress Markers (Elevated)
Show evidence (1 reference)
PMID:24557875 SUPPORT
"Mitochondrial dysfunctions, e.g. lowered ATP production, may play a role in the onset of ME/CFS symptoms"
Study demonstrates oxidative and nitrosative stress pathways contribute to ME/CFS pathophysiology.
PEM-Associated Purine and Hypermetabolic Shift (Altered)
Context: During self-reported post-exertional malaise
Show evidence (2 references)
PMID:31277442 SUPPORT Human Clinical
"Increased excretion of urine metabolites within the 7-day response period indicated a hypermetabolic event was occurring."
Human metabolomics supports PEM as a measurable metabolic response period rather than fatigue alone.
PMID:31277442 SUPPORT Human Clinical
"These findings suggest the primary events associated with PEM were due to hypoacetylation and metabolite loss during the acute PEM response."
The paper links acute PEM with metabolite loss and hypoacetylation, supporting a PEM-specific biochemical marker entry.
{ }

Source YAML

click to show 
name: Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
creation_date: '2025-12-06T01:38:31Z'
updated_date: '2026-05-22T04:15:00Z'
category: Complex
parents:
- Neurological Disorder
- Immune Disorder
disease_term:
  preferred_term: myalgic encephalomyelitis
  term:
    id: MONDO:0005404
    label: myalgic encephalomeyelitis/chronic fatigue syndrome
synonyms:
- ME/CFS
- Chronic Fatigue Syndrome
- Systemic Exertion Intolerance Disease
pathophysiology:
- name: Innate Immune Hyperreactivity
  description: Exaggerated innate immune responses to microbial ligands, with exercise-triggered increases in proinflammatory signals, complement activation, and oxidative stress that contribute to post-exertional malaise.
  cell_types:
  - preferred_term: Natural Killer Cell
    term:
      id: CL:0000623
      label: natural killer cell
  - preferred_term: Monocyte
    term:
      id: CL:0000576
      label: monocyte
  biological_processes:
  - preferred_term: Innate Immune Response
    term:
      id: GO:0045087
      label: innate immune response
  - preferred_term: Complement Activation
    term:
      id: GO:0006956
      label: complement activation
  evidence:
  - reference: PMID:37226227
    reference_title: "Biomarkers for myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): a systematic review."
    supports: SUPPORT
    snippet: several studies validated the involvement of immune dysfunction in the pathology of ME/CFS and the use of lymphocytes as a model to investigate the pathomechanism of illness
    explanation: The BMC Medicine systematic review identifies immune dysfunction as the most reproducible finding in ME/CFS.
- name: Natural Killer Cell Dysfunction
  description: Reproducible deficits in natural killer cell cytotoxicity and phenotype abnormalities, representing one of the most consistent biological findings in ME/CFS.
  cell_types:
  - preferred_term: Natural Killer Cell
    term:
      id: CL:0000623
      label: natural killer cell
  evidence:
  - reference: PMID:31727160
    reference_title: "A systematic review of natural killer cells profile and cytotoxic function in myalgic encephalomyelitis/chronic fatigue syndrome."
    supports: SUPPORT
    snippet: Impaired NK cell cytotoxicity remained the most consistent immunological report across all publications
    explanation: Systematic review of 17 studies confirms NK cell dysfunction as the most reproducible immunological finding in ME/CFS.
  - reference: PMID:27245705
    reference_title: "Novel identification and characterisation of Transient receptor potential melastatin 3 ion channels on Natural Killer cells and B lymphocytes: effects on cell signalling in Chronic fatigue syndrome/Myalgic encephalomyelitis patients."
    supports: SUPPORT
    snippet: There was a significant reduction of TRPM3 surface expression on CD19(+) B cells (1.56 ± 0.191) and CD56(bright) NK cells (17.37 % ± 5.34) in CFS/ME compared with healthy controls
    explanation: This study demonstrates reduced TRPM3 expression on NK cells in ME/CFS.
  - reference: DOI:10.3389/fimmu.2024.1440643
    reference_title: Meta-analysis of natural killer cell cytotoxicity in myalgic encephalomyelitis/chronic fatigue syndrome
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >
      Reduced natural killer (NK) cell cytotoxicity is the most consistent immune
      finding in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS).
    explanation: >
      The 2024 meta-analysis from the deep-research report strengthens the NK-cell
      dysfunction assertion with a larger synthesis than the older systematic
      review already cited.
- name: Adaptive Immune Memory Dysregulation
  description: B-cell compartment shifts suggest chronic antigenic stimulation, with increased naive B cells and decreased class-switched memory B cells consistent with impaired adaptive immune memory maturation.
  cell_types:
  - preferred_term: naive B cell
    term:
      id: CL:0000788
      label: naive B cell
  - preferred_term: class switched memory B cell
    term:
      id: CL:0000972
      label: class switched memory B cell
  biological_processes:
  - preferred_term: B cell differentiation
    term:
      id: GO:0030183
      label: B cell differentiation
  evidence:
  - reference: DOI:10.1038/s41467-024-45107-3
    reference_title: Deep phenotyping of post-infectious myalgic encephalomyelitis/chronic fatigue syndrome
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Immune profiling suggested chronic antigenic stimulation with increase in naïve and decrease in switched memory B-cells."
    explanation: The NIH deep-phenotyping cohort directly supports a B-cell compartment shift consistent with chronic antigenic stimulation in post-infectious ME/CFS.
- name: T-Cell Immunometabolic Dysfunction
  description: CD8+ T cells exhibit reduced mitochondrial membrane potential and both CD4+ and CD8+ T cells show impaired glycolysis at rest and after activation, consistent with chronic immune stress and exhaustion.
  cell_types:
  - preferred_term: CD8+ T Cell
    term:
      id: CL:0000625
      label: CD8-positive, alpha-beta T cell
  - preferred_term: CD4+ T Cell
    term:
      id: CL:0000624
      label: CD4-positive, alpha-beta T cell
  biological_processes:
  - preferred_term: T Cell Activation
    term:
      id: GO:0042110
      label: T cell activation
  - preferred_term: Glycolysis
    term:
      id: GO:0006096
      label: glycolytic process
  evidence:
  - reference: PMID:37226227
    reference_title: "Biomarkers for myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): a systematic review."
    supports: SUPPORT
    snippet: Potential biomarkers ranged from genetic/epigenetic (19.8%), immunological (29.7%), metabolomics/mitochondrial/microbiome (14.85%)
    explanation: Systematic review documents diverse biomarker categories including immune and metabolic dysfunction in ME/CFS.
- name: CD8+ T Cell Exhaustion
  description: CD8+ T cell effector memory subsets show exhaustion-associated transcription factor activity, altered chromatin accessibility, and metabolic reprogramming, indicating adaptive immune dysfunction after symptom provocation.
  cell_types:
  - preferred_term: CD8+ T cell
    term:
      id: CL:0000625
      label: CD8-positive, alpha-beta T cell
  biological_processes:
  - preferred_term: exhausted T cell differentiation
    term:
      id: GO:0160083
      label: exhausted T cell differentiation
  evidence:
  - reference: DOI:10.1073/pnas.2415119121
    reference_title: Transcriptional reprogramming primes CD8+ T cells toward exhaustion in Myalgic encephalomyelitis/chronic fatigue syndrome
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We observed upregulation of key transcription factors associated with T cell exhaustion in CD8+ T cell effector memory subsets, as well as an altered chromatin landscape and metabolic reprogramming consistent with an exhausted immune cell state."
    explanation: Multiomic human T-cell profiling supports CD8+ T-cell exhaustion programming as a ME/CFS pathophysiology mechanism.
  - reference: DOI:10.1073/pnas.2415119121
    reference_title: Transcriptional reprogramming primes CD8+ T cells toward exhaustion in Myalgic encephalomyelitis/chronic fatigue syndrome
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Together, these data identify T cell exhaustion as a component of ME, a finding which may provide a basis for future therapies, such as checkpoint blockade, metabolic interventions, or drugs that target chronic viral infections."
    explanation: The authors explicitly identify T-cell exhaustion as a component of ME and link it to therapeutic rationale.
- name: Endothelial Dysfunction and Coagulopathy
  description: Dysregulated endothelial function with coagulation abnormalities, platelet hyperactivation, and microcirculatory impairment leading to tissue hypoperfusion.
  cell_types:
  - preferred_term: Endothelial Cell
    term:
      id: CL:0000115
      label: endothelial cell
  - preferred_term: Platelet
    term:
      id: CL:0000233
      label: platelet
  biological_processes:
  - preferred_term: Blood Coagulation
    term:
      id: GO:0007596
      label: blood coagulation
  - preferred_term: Platelet Activation
    term:
      id: GO:0030168
      label: platelet activation
  evidence:
  - reference: PMID:36730360
    reference_title: "Endothelial dysfunction in ME/CFS patients."
    supports: SUPPORT
    snippet: ME/CFS patients had markedly reduced FMD compared to healthy controls at baseline (5.1% vs. 8.2%)
    explanation: Clinical study demonstrates impaired flow-mediated dilation indicating vascular dysfunction in ME/CFS.
  - reference: DOI:10.1186/s12933-024-02315-x
    reference_title: Data-independent LC-MS/MS analysis of ME/CFS plasma reveals a dysregulated coagulation system, endothelial dysfunction, downregulation of complement machinery
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >
      Proteins related to clotting processes – thrombospondin-1 (important in
      platelet activation), platelet factor 4, and protein S – were
      differentially expressed in the ME/CFS group, suggestive of a dysregulated
      coagulation system and abnormal endothelial function.
    explanation: >
      The deep-research report highlighted this 2024 plasma proteomics study as
      direct protein-level support for the endothelial/coagulation mechanism.
- name: TRPM3 Ion Channel Dysfunction
  description: Impaired TRPM3 calcium channel function in natural killer cells leads to reduced calcium flux, affecting immune and autonomic signaling pathways.
  cell_types:
  - preferred_term: Natural Killer Cell
    term:
      id: CL:0000623
      label: natural killer cell
  biological_processes:
  - preferred_term: Calcium Ion Transmembrane Transport
    term:
      id: GO:0070588
      label: calcium ion transmembrane transport
  evidence:
  - reference: PMID:31736966
    reference_title: "Naltrexone Restores Impaired Transient Receptor Potential Melastatin 3 Ion Channel Function in Natural Killer Cells From Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Patients."
    supports: SUPPORT
    snippet: TRPM3 channel activity was restored in IL-2 stimulated NK cells isolated from ME/CFS patients after incubation for 24 h with NTX
    explanation: Research demonstrates impaired TRPM3 function in ME/CFS NK cells and potential for pharmacological restoration.
- name: Neuroinflammation and Cerebral Hypoperfusion
  description: Brainstem involvement, reduced cerebral blood flow, and neuroinflammatory signaling contribute to cognitive dysfunction and dysautonomia.
  locations:
  - preferred_term: Brain
    term:
      id: UBERON:0000955
      label: brain
  - preferred_term: Brainstem
    term:
      id: UBERON:0002298
      label: brainstem
  evidence:
  - reference: PMID:32873297
    reference_title: "Neuroimaging characteristics of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): a systematic review."
    supports: SUPPORT
    snippet: Additional brain area recruitment for cognitive tasks and abnormalities in the brain stem are frequent observations
    explanation: Systematic review of 63 neuroimaging studies supports CNS involvement in ME/CFS.
- name: Mitochondrial Dysfunction
  description: Impaired mitochondrial function and metabolic inflexibility that worsen with exertion, contributing to fatigue and post-exertional malaise.
  cellular_components:
  - preferred_term: Mitochondrion
    term:
      id: GO:0005739
      label: mitochondrion
  biological_processes:
  - preferred_term: Fatty Acid Beta-Oxidation
    term:
      id: GO:0006635
      label: fatty acid beta-oxidation
  - preferred_term: Response to Oxidative Stress
    term:
      id: GO:0006979
      label: response to oxidative stress
  evidence:
  - reference: PMID:22837795
    reference_title: "Mitochondrial dysfunction and the pathophysiology of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)."
    supports: SUPPORT
    snippet: all patients tested have measureable mitochondrial dysfunction which correlates with the severity of the illness  # codespell:ignore-line
    explanation: ATP Profile testing demonstrates mitochondrial dysfunction in ME/CFS patients correlating with disease severity.
- name: Impaired Peripheral Oxygen Extraction and Microcirculation
  description: >
    Physical activity may unmask reduced systemic oxygen extraction and oxidative
    phosphorylation capacity, with microcirculatory and mitochondrial dysfunction
    maintained by latent immune activation and impairing peripheral bioenergetics.
  cell_types:
  - preferred_term: Endothelial Cell
    term:
      id: CL:0000115
      label: endothelial cell
  biological_processes:
  - preferred_term: Peripheral blood circulation
    term:
      id: GO:0008015
      label: blood circulation
    modifier: DECREASED
  - preferred_term: Oxidative phosphorylation capacity
    term:
      id: GO:0006119
      label: oxidative phosphorylation
    modifier: DECREASED
  evidence:
  - reference: PMID:39240417
    reference_title: "Towards an understanding of physical activity-induced post-exertional malaise: Insights into microvascular alterations and immunometabolic interactions in post-COVID condition and myalgic encephalomyelitis/chronic fatigue syndrome."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Upon physical activity, affected patients exhibit a reduced systemic oxygen extraction and oxidative phosphorylation capacity."
    explanation: Review-level synthesis supports impaired oxygen extraction and oxidative phosphorylation during activity as a proximal PEM mechanism.
  - reference: PMID:33577778
    reference_title: "Insights From Invasive Cardiopulmonary Exercise Testing of Patients With Myalgic Encephalomyelitis/Chronic Fatigue Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "These results identify two types of peripheral neurovascular dysregulation that are biologically plausible contributors to ME/CFS exertional intolerance-depressed Qc from impaired venous return, and impaired peripheral oxygen extraction."
    explanation: Invasive cardiopulmonary exercise testing provides direct human hemodynamic evidence for impaired venous return and peripheral oxygen extraction during exertional intolerance.
  downstream:
  - target: Exertion-Triggered Skeletal Muscle Disturbance
    description: >
      Reduced oxygen delivery or extraction is proposed to force skeletal muscle
      toward anaerobic metabolism and ionic stress during exertion.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - reduced tissue perfusion
    - reduced oxygen utilization
    - impaired peripheral bioenergetics
    hypothesis_groups:
    - exertion_perfusion_muscle_immunometabolic_pem_model
- name: Exertion-Triggered Skeletal Muscle Disturbance
  description: >
    Skeletal muscle may undergo exertion-amplified mitochondrial, ionic, and
    tissue stress, including repeated damage and regeneration in some
    post-infectious ME/CFS patients, contributing to exertional intolerance and
    post-exertional malaise.
  cell_types:
  - preferred_term: Skeletal muscle cell
    term:
      id: CL:0000188
      label: cell of skeletal muscle
  biological_processes:
  - preferred_term: Oxidative phosphorylation
    term:
      id: GO:0006119
      label: oxidative phosphorylation
    modifier: DECREASED
  - preferred_term: Response to hypoxia
    term:
      id: GO:0001666
      label: response to hypoxia
    modifier: INCREASED
  evidence:
  - reference: PMID:39727052
    reference_title: "Key Pathophysiological Role of Skeletal Muscle Disturbance in Post COVID and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): Accumulated Evidence."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "recent studies provide strong evidence for mitochondrial dysfunction in skeletal muscle tissue in ME/CFS."
    explanation: Review-level synthesis supports skeletal muscle tissue as the relevant compartment for mitochondrial dysfunction in ME/CFS.
  - reference: PMID:39727052
    reference_title: "Key Pathophysiological Role of Skeletal Muscle Disturbance in Post COVID and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): Accumulated Evidence."
    supports: PARTIAL
    evidence_source: OTHER
    snippet: "This energy deficit is the most likely cause of exertional intolerance and post exertional malaise and is further aggravated by exertion."
    explanation: The review explicitly proposes skeletal muscle energy deficit as a likely cause of exertional intolerance and PEM, but this causal claim remains model-level rather than proven by perturbation.
  downstream:
  - target: Delayed PEM Immunometabolic Amplification
    description: >
      Muscle ionic and energy disturbance may generate metabolites and stress
      signals that amplify immune, autonomic, and CNS symptoms after activity.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    hypothesis_groups:
    - exertion_perfusion_muscle_immunometabolic_pem_model
- name: Delayed PEM Immunometabolic Amplification
  description: >
    Activity-induced metabolites and oxidative mediators may trigger local and
    systemic immune activation, intensifying bioenergetic inflexibility,
    muscular ionic disturbance, autonomic dysfunction, and CNS symptom worsening
    after a delay.
  biological_processes:
  - preferred_term: Innate immune response
    term:
      id: GO:0045087
      label: innate immune response
    modifier: INCREASED
  - preferred_term: Glycolytic process
    term:
      id: GO:0006096
      label: glycolytic process
  - preferred_term: Response to oxidative stress
    term:
      id: GO:0006979
      label: response to oxidative stress
    modifier: INCREASED
  evidence:
  - reference: PMID:39240417
    reference_title: "Towards an understanding of physical activity-induced post-exertional malaise: Insights into microvascular alterations and immunometabolic interactions in post-COVID condition and myalgic encephalomyelitis/chronic fatigue syndrome."
    supports: PARTIAL
    evidence_source: OTHER
    snippet: "The accumulation of molecules such as lactate, reactive oxygen species or prostaglandins might trigger local and systemic immune activation."
    explanation: The review provides a plausible metabolite-to-immune activation bridge, but frames the step as a hypothesis needing direct causal testing.
  - reference: PMID:39240417
    reference_title: "Towards an understanding of physical activity-induced post-exertional malaise: Insights into microvascular alterations and immunometabolic interactions in post-COVID condition and myalgic encephalomyelitis/chronic fatigue syndrome."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Subsequent intensification of bioenergetic inflexibilities, muscular ionic disturbances and modulation of central nervous system functions can lead to an exacerbation of existing pathologies and symptoms."
    explanation: Supports the delayed amplification concept linking peripheral metabolic disturbance with broader symptom exacerbation.
  - reference: PMID:38232699
    reference_title: "Single-cell transcriptomics of the immune system in ME/CFS at baseline and following symptom provocation."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "Comparing the transcriptome at baseline and postexercise challenge, we discover patterns indicative of improper platelet activation in patients, with minimal changes elsewhere in the immune system."
    explanation: Post-exercise single-cell data support symptom-provocation immune/platelet dysregulation, while qualifying broad cytokine-amplification claims.
  downstream:
  - target: Post-Exertional Malaise
    description: >
      Immunometabolic amplification is proposed to explain delayed worsening of
      existing ME/CFS symptoms after exertion.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    hypothesis_groups:
    - exertion_perfusion_muscle_immunometabolic_pem_model
mechanistic_hypotheses:
- hypothesis_group_id: exertion_perfusion_muscle_immunometabolic_pem_model
  hypothesis_label: Exertion-Perfusion-Muscle Immunometabolic PEM Model
  status: EMERGING
  description: >
    Physical or cognitive exertion unmasks impaired peripheral oxygen
    extraction, microcirculation, skeletal muscle oxidative phosphorylation, and
    ionic homeostasis; local metabolites and inflammatory mediators then amplify
    autonomic and central nervous system dysfunction into delayed
    post-exertional malaise.
  notes: >
    Seeded for issue 3665 as an integrated working model rather than an
    established causal chain. It groups microvascular, skeletal-muscle,
    mitochondrial, immune-metabolic, autonomic, and CNS amplification mechanisms
    that may be subtype-specific or temporally staged. OpenScientist review in
    kb/hypotheses/Myalgic_Encephalomyelitis_Chronic_Fatigue_Syndrome/exertion_perfusion_muscle_immunometabolic_pem_model/openscientist.md
    judged the model partially supported and recommended retaining EMERGING
    status because individual nodes have human evidence but the sequential
    causal chain, ionic-homeostasis step, and subtype boundaries remain
    unresolved.
  evidence:
  - reference: PMID:39240417
    reference_title: "Towards an understanding of physical activity-induced post-exertional malaise: Insights into microvascular alterations and immunometabolic interactions in post-COVID condition and myalgic encephalomyelitis/chronic fatigue syndrome."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Aggravating deficits in tissue perfusion and oxygen utilization during activities cause exertional intolerance that are frequently accompanied by tachycardia, dyspnea, early cessation of activity and elicit downstream metabolic effects."
    explanation: Review-level synthesis supports an exertion-to-perfusion/oxygen-utilization-to-metabolic-effects chain relevant to PEM.
  - reference: PMID:31277442
    reference_title: "Post-Exertional Malaise Is Associated with Hypermetabolism, Hypoacetylation and Purine Metabolism Deregulation in ME/CFS Cases."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The principal biochemical change related to the 7-day severity of PEM was the fall in the purine metabolite, hypoxanthine."
    explanation: Human observational metabolomics links PEM severity over a 7-day window to a biochemical change in purine metabolism.
  - reference: PMID:8423875
    reference_title: "Central basis of muscle fatigue in chronic fatigue syndrome."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "The results indicate that patients with CFS have (1) normal fatigability and metabolism at both the intracellular and systemic levels, (2) normal muscle membrane function and excitation-contraction coupling, and (3) an inability to fully activate skeletal muscle during intense, sustained exercise."
    explanation: This older exercise physiology study qualifies a purely peripheral muscle model by supporting a central activation component in some patients.
  - reference: PMID:42212259
    reference_title: "Cardiopulmonary exercise test results do not change over two sequential days in patients with chronic fatigue syndrome."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "The data do not support using the 2-day CPET protocol to define PEM or disability."
    explanation: This 2026 replication attempt qualifies the model by challenging universal reliance on day-2 CPET decline as an objective PEM marker.
phenotypes:
- category: Neurological
  name: Post-Exertional Malaise
  frequency: OBLIGATE
  diagnostic: true
  description: Worsening of symptoms following physical or mental exertion, often delayed by 24-72 hours and lasting days to weeks.
  notes: Cardinal feature required for diagnosis
  phenotype_term:
    preferred_term: Post-Exertional Malaise
    term:
      id: HP:0030973
      label: Postexertional symptom exacerbation
  evidence:
  - reference: PMID:25584525
    reference_title: "Problems in defining post-exertional malaise."
    supports: SUPPORT
    snippet: Post-exertional malaise (PEM) is a cardinal symptom of the illnesses referred to as Myalgic Encephalomyelitis (ME), Myalgic Encephalomyelitis/chronic fatigue syndrome (ME/CFS), and chronic fatigue syndrome (CFS)
    explanation: PEM is universally recognized as the cardinal feature of ME/CFS.
- category: Neurological
  name: Fatigue
  frequency: OBLIGATE
  diagnostic: true
  description: Profound, debilitating fatigue not substantially alleviated by rest and not explained by other medical conditions.
  phenotype_term:
    preferred_term: Fatigue
    term:
      id: HP:0012378
      label: Fatigue
  evidence:
  - reference: PMID:25695122
    supports: SUPPORT
    snippet: ME/CFS can cause significant impairment and disability
    explanation: The IOM report defines fatigue as a core diagnostic criterion for ME/CFS.
- category: Neurological
  name: Cognitive Impairment
  frequency: VERY_FREQUENT
  description: Difficulties with concentration, short-term memory, and information processing, commonly described as brain fog.
  phenotype_term:
    preferred_term: Cognitive Impairment
    term:
      id: HP:0100543
      label: Cognitive impairment
  evidence:
  - reference: PMID:35140252
    reference_title: "Systematic review and meta-analysis of cognitive impairment in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)."
    supports: SUPPORT
    snippet: The clinical picture typically affects visuo-spatial immediate memory (g = - 0.55, p = 0.007), reading speed (g = - 0.82, p = 0.0001) and graphics gesture (g = - 0.59, p = 0.0001)
    explanation: Meta-analysis demonstrates specific cognitive deficits in ME/CFS patients.
- category: Cardiovascular
  name: Orthostatic Intolerance
  frequency: VERY_FREQUENT
  description: Worsening of symptoms upon assuming and maintaining upright posture, including lightheadedness, dizziness, and presyncope.
  phenotype_term:
    preferred_term: Orthostatic Intolerance
    term:
      id: HP:0001278
      label: Orthostatic hypotension
  evidence:
  - reference: PMID:31159884
    reference_title: "Orthostatic intolerance in chronic fatigue syndrome."
    supports: SUPPORT
    snippet: Dizziness and lightheadedness were found in 41% of recumbent CFS subjects and in 72% of standing CFS subjects
    explanation: Orthostatic symptoms are highly prevalent in ME/CFS patients.
  - reference: DOI:10.1186/s12967-024-05148-0
    reference_title: "Endothelial dysfunction and inflammation biomarkers in ME/CFS and long COVID"
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: >
      Four ME/CFS patients (13%), 1 with long COVID (4%), and 1 healthy control
      (3%) presented postural orthostatic tachycardia syndrome (POTS) using the
      10-min NASA lean test.
    explanation: >
      This deep-research citation supports orthostatic intolerance in a subset of
      ME/CFS patients measured by standardized lean testing.
- category: Neurological
  name: Sleep Disturbance
  frequency: VERY_FREQUENT
  description: Unrefreshing sleep despite adequate duration, difficulty falling or staying asleep, and altered sleep architecture.
  phenotype_term:
    preferred_term: Sleep Disturbance
    term:
      id: HP:0002360
      label: Sleep disturbance
  evidence:
  - reference: PMID:36948138
    reference_title: "Objective sleep measures in chronic fatigue syndrome patients: A systematic review and meta-analysis."
    supports: SUPPORT
    snippet: Adult ME/CFS patients spend longer time in bed, longer sleep onset latency, longer awake time after sleep onset, reduced sleep efficiency
    explanation: Meta-analysis of objective sleep measures demonstrates sleep architecture abnormalities in ME/CFS.
- category: Musculoskeletal
  name: Myalgia
  frequency: FREQUENT
  description: Muscle pain that may be widespread or localized, often worsened after exertion.
  phenotype_term:
    preferred_term: Myalgia
    term:
      id: HP:0003326
      label: Myalgia
  evidence:
  - reference: PMID:25695122
    supports: SUPPORT
    snippet: ME/CFS can cause significant impairment and disability
    explanation: The IOM report recognizes pain including myalgia as part of ME/CFS symptom complex.
- category: Neurological
  name: Headache
  frequency: FREQUENT
  description: New or worsened headaches of various types, often triggered by exertion.
  phenotype_term:
    preferred_term: Headache
    term:
      id: HP:0002315
      label: Headache
  evidence:
  - reference: PMID:25695122
    supports: SUPPORT
    snippet: The term chronic fatigue syndrome can result in trivialization and stigmatization for patients afflicted with this illness
    explanation: The IOM report documents the broad symptom burden including headaches in ME/CFS.
- category: Immune
  name: Recurrent Infections
  phenotype_term:
    preferred_term: Recurrent Infections
    term:
      id: HP:0002719
      label: Recurrent infections
  frequency: OCCASIONAL
  description: Increased susceptibility to viral and bacterial infections, including flu-like symptoms and sore throat.
  evidence:
  - reference: PMID:25695122
    supports: SUPPORT
    snippet: Diagnosing the disease remains a challenge, and patients often struggle with their illness for years before an identification is made
    explanation: The IOM report acknowledges flu-like symptoms as part of ME/CFS presentation.
- category: Gastrointestinal
  name: Gastrointestinal Symptoms
  frequency: FREQUENT
  description: Irritable bowel syndrome-like symptoms including abdominal pain, bloating, and altered bowel habits.
  notes: Many patients meet criteria for IBS
  evidence:
  - reference: PMID:25433843
    reference_title: "Evidence for the existence of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) with and without abdominal discomfort (irritable bowel) syndrome."
    supports: SUPPORT
    snippet: the cluster analysis-generated diagnosis of abdominal discomfort syndrome (ADS) was significantly higher in subjects with ME/CFS (59.6%) than in those with CF (17.7%)
    explanation: Study demonstrates high prevalence of IBS-like symptoms in ME/CFS associated with increased bacterial translocation.
- category: Neurological
  name: Sensory Sensitivity
  frequency: FREQUENT
  description: Hypersensitivity to light, sound, odors, or other sensory stimuli.
  evidence:
  - reference: PMID:25695122
    supports: SUPPORT
    snippet: Beyond Myalgic Encephalomyelitis/Chronic Fatigue Syndrome proposes new diagnostic clinical criteria for ME/CFS
    explanation: The IOM criteria recognize sensory sensitivities as part of the ME/CFS symptom complex.
biochemical:
- name: Natural Killer Cell Cytotoxicity
  presence: Decreased
  evidence:
  - reference: PMID:31727160
    reference_title: "A systematic review of natural killer cells profile and cytotoxic function in myalgic encephalomyelitis/chronic fatigue syndrome."
    supports: SUPPORT
    snippet: Impaired NK cell cytotoxicity remained the most consistent immunological report across all publications
    explanation: Systematic review confirms NK cell dysfunction as the most reproducible biomarker finding in ME/CFS.
  - reference: DOI:10.3389/fimmu.2024.1440643
    reference_title: Meta-analysis of natural killer cell cytotoxicity in myalgic encephalomyelitis/chronic fatigue syndrome
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >
      Cytotoxicity in ME/CFS was significantly reduced to about half of healthy
      control levels, with an overall Hedges’ g of 0.96 (0.75–1.18).
    explanation: >
      The 2024 meta-analysis provides quantitative support for decreased NK-cell
      cytotoxicity as a biochemical/functional immune marker.
- name: Inflammatory Cytokines
  presence: Elevated
  context: Early disease and after exertion
  evidence:
  - reference: PMID:28760971
    reference_title: "Cytokine signature associated with disease severity in chronic fatigue syndrome patients."
    supports: SUPPORT
    snippet: Seventeen cytokines had a statistically significant upward linear trend that correlated with ME/CFS severity
    explanation: Stanford study identifies cytokine signature correlating with disease severity including 13 proinflammatory cytokines.
- name: Oxidative Stress Markers
  presence: Elevated
  evidence:
  - reference: PMID:24557875
    reference_title: "Mitochondrial dysfunctions in myalgic encephalomyelitis/chronic fatigue syndrome explained by activated immuno-inflammatory, oxidative and nitrosative stress pathways."
    supports: SUPPORT
    snippet: Mitochondrial dysfunctions, e.g. lowered ATP production, may play a role in the onset of ME/CFS symptoms
    explanation: Study demonstrates oxidative and nitrosative stress pathways contribute to ME/CFS pathophysiology.
- name: PEM-Associated Purine and Hypermetabolic Shift
  presence: Altered
  context: During self-reported post-exertional malaise
  evidence:
  - reference: PMID:31277442
    reference_title: "Post-Exertional Malaise Is Associated with Hypermetabolism, Hypoacetylation and Purine Metabolism Deregulation in ME/CFS Cases."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Increased excretion of urine metabolites within the 7-day response period indicated a hypermetabolic event was occurring."
    explanation: Human metabolomics supports PEM as a measurable metabolic response period rather than fatigue alone.
  - reference: PMID:31277442
    reference_title: "Post-Exertional Malaise Is Associated with Hypermetabolism, Hypoacetylation and Purine Metabolism Deregulation in ME/CFS Cases."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "These findings suggest the primary events associated with PEM were due to hypoacetylation and metabolite loss during the acute PEM response."
    explanation: The paper links acute PEM with metabolite loss and hypoacetylation, supporting a PEM-specific biochemical marker entry.
genetic:
- name: HLA-DRB1
  association: Susceptibility
  notes: Some HLA alleles associated with increased risk
  evidence:
  - reference: PMID:32744306
    reference_title: "Genetic risk factors of ME/CFS: a critical review."
    supports: PARTIAL
    snippet: evidence that it has a heritable component, ME/CFS has not yet benefited from the advances in technology and analytical tools that have improved our understanding of many other complex diseases
    explanation: Critical review documents evidence for heritable component in ME/CFS.
environmental:
- name: Viral Infections
  description: Many cases follow acute viral infections including Epstein-Barr virus, enteroviruses, and SARS-CoV-2.
  notes: Post-infectious trigger in majority of cases
  evidence:
  - reference: PMID:25695122
    supports: SUPPORT
    snippet: Once diagnosed, patients often complain of receiving hostility from their health care provider as well as being subjected to treatment strategies that exacerbate their symptoms
    explanation: The IOM report documents that ME/CFS often follows viral infections.
- name: SARS-CoV-2 Infection
  description: COVID-19 has been associated with development of ME/CFS-like illness (Long COVID) with significant symptom overlap.
  notes: Post-COVID condition shares many features with ME/CFS
  evidence:
  - reference: PMID:33925784
    reference_title: "Long COVID and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)-A Systemic Review and Comparison of Clinical Presentation and Symptomatology."
    supports: SUPPORT
    snippet: twenty-five out of 29 known ME/CFS symptoms were reported by at least one selected long COVID study
    explanation: Systematic review demonstrates substantial symptom overlap between long COVID and ME/CFS.
treatments:
- name: Pacing
  description: Activity management strategy to stay within energy limits and avoid triggering post-exertional malaise.
  notes: Currently the most widely recommended management approach
  evidence:
  - reference: PMID:37838675
    reference_title: "A scoping review of 'Pacing' for management of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): lessons learned for the long COVID pandemic."
    supports: SUPPORT
    snippet: it typically comprises regulating activity to avoid post exertional malaise (PEM), the worsening of symptoms after an activity
    explanation: Scoping review confirms pacing is the primary self-management strategy for ME/CFS.
  treatment_term:
    preferred_term: supportive care
    term:
      id: MAXO:0000950
      label: supportive care
- name: Symptomatic Treatment
  description: Treatment of individual symptoms including sleep disturbance, pain, and orthostatic intolerance.
  evidence:
  - reference: PMID:25695122
    supports: SUPPORT
    snippet: Beyond Myalgic Encephalomyelitis/Chronic Fatigue Syndrome will be a valuable resource to promote the prompt diagnosis of patients with this complex, multisystem, and often devastating disorder
    explanation: The IOM report recommends symptomatic treatment approaches.
  treatment_term:
    preferred_term: supportive care
    term:
      id: MAXO:0000950
      label: supportive care
- name: Low-Dose Naltrexone
  description: Off-label use targeting TRPM3 ion channel dysfunction and neuroinflammation.
  notes: Under investigation; not yet proven in randomized trials
  evidence:
  - reference: PMID:31736966
    reference_title: "Naltrexone Restores Impaired Transient Receptor Potential Melastatin 3 Ion Channel Function in Natural Killer Cells From Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Patients."
    supports: PARTIAL
    snippet: TRPM3 channel activity was restored in IL-2 stimulated NK cells isolated from ME/CFS patients after incubation for 24 h with NTX
    explanation: In vitro evidence supports naltrexone restoring TRPM3 function in ME/CFS NK cells.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: naltrexone
      term:
        id: CHEBI:7465
        label: naltrexone
- name: Plasma Exchange
  description: Apheresis procedure to remove pathogenic circulating factors, showing promise in post-COVID ME/CFS cases.
  notes: Novel therapeutic approach; case report evidence only
  evidence:
  - reference: PMID:42158223
    reference_title: "Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Successful Therapeutic Plasma Exchange Treatment After SARS-CoV-2 Infection-A Case Report."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Our successful case highlights the need to investigate novel therapeutic approaches, including plasma exchange."
    explanation: Case report documents successful plasma exchange treatment in a post-COVID ME/CFS patient, supporting investigation of this therapeutic approach.
  treatment_term:
    preferred_term: plasmapheresis
    term:
      id: NCIT:C15304
      label: Plasmapheresis
discussions:
- discussion_id: gap_mecfs_pem_causal_ordering
  prompt: >
    Which causal edge best connects exertion to delayed multi-system symptom
    worsening in ME/CFS: impaired microvascular oxygen delivery/extraction,
    skeletal muscle ionic and mitochondrial disturbance, immune-metabolic
    signaling, autonomic dysfunction, central nervous system amplification, or a
    subtype-specific combination?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#Impaired Peripheral Oxygen Extraction and Microcirculation
  - pathophysiology#Exertion-Triggered Skeletal Muscle Disturbance
  - pathophysiology#Delayed PEM Immunometabolic Amplification
  - phenotype#Post-Exertional Malaise
  rationale: >
    Evidence links PEM to impaired oxygen extraction, skeletal muscle
    mitochondrial/ionic disturbance, and short-window metabolomic changes, but
    much of the causal ordering is inferred from review-level synthesis,
    observational cohorts, and post-exertion association rather than
    perturbation or longitudinal mediation evidence. OpenScientist highlighted
    unresolved ionic homeostasis, inconsistent post-exercise immune activation,
    and unknown subtype boundaries as priority gaps.
  proposed_experiments:
  - experiment_id: exp_mecfs_pem_serial_exertion_perfusion_multiomics
    name: Serial exertion-challenge perfusion and muscle multi-omics cohort
    description: >
      Enroll ME/CFS patients stratified by PEM severity plus matched controls;
      perform a standardized submaximal or 2-day exertion challenge; measure
      muscle oxygen extraction, tissue perfusion, intracellular sodium or muscle
      calcium dynamics, muscle injury markers, blood and urine metabolomics,
      cytokines, single-cell immune and platelet states, autonomic
      physiology, and symptom trajectories before exertion and at immediate,
      24-hour, 48-hour, and 7-day time points.
    experiment_type:
      preferred_term: longitudinal exertion-challenge cohort
    model_systems:
    - name: Human ME/CFS exertion-challenge cohort
      description: >
        Patient cohort designed to temporally order peripheral perfusion,
        skeletal muscle, metabolic, immune, autonomic, and symptom readouts
        during PEM induction and recovery.
      experimental_model_type: OTHER
      organism:
        preferred_term: human
        term:
          id: NCBITaxon:9606
          label: Homo sapiens
    decision_criterion: >
      A causal ordering is supported if impaired oxygen extraction or muscle
      ionic/mitochondrial disturbance precedes metabolite and immune changes and
      quantitatively mediates delayed PEM severity; competing models are favored
      if autonomic or CNS changes precede peripheral abnormalities.
    would_support:
    - pathophysiology#Impaired Peripheral Oxygen Extraction and Microcirculation
    - pathophysiology#Exertion-Triggered Skeletal Muscle Disturbance
    - pathophysiology#Delayed PEM Immunometabolic Amplification
    would_refute:
    - mechanistic_hypothesis#exertion_perfusion_muscle_immunometabolic_pem_model
notes: ME/CFS is a complex, multisystem disease with no established cure. Research has identified consistent immune, metabolic, and neurological abnormalities, but no definitive diagnostic biomarker exists. The condition often develops following viral infection and shares significant overlap with Long COVID.
references:
- reference: DOI:10.1126/science.abo1261
  title: Understanding myalgic encephalomyelitis
  found_in:
  - Myalgic_Encephalomyelitis_Chronic_Fatigue_Syndrome-deep-research-perplexity.md
  findings: []
- reference: DOI:10.3389/fimmu.2024.1386607
  title: "Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: the biology of a neglected disease"
  found_in:
  - Myalgic_Encephalomyelitis_Chronic_Fatigue_Syndrome-deep-research-falcon.md
  - Myalgic_Encephalomyelitis_Chronic_Fatigue_Syndrome-deep-research-perplexity.md
  findings: []
- reference: DOI:10.3389/fneur.2022.877772
  title: Molecular Mechanisms of Neuroinflammation in ME/CFS and Long COVID to Sustain Disease and Promote Relapses
  found_in:
  - Myalgic_Encephalomyelitis_Chronic_Fatigue_Syndrome-deep-research-perplexity.md
  findings: []
📚

References & Deep Research

References

3
DOI:10.1126/science.abo1261
Understanding myalgic encephalomyelitis
No top-level findings curated for this source.
DOI:10.3389/fimmu.2024.1386607
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: the biology of a neglected disease
No top-level findings curated for this source.
DOI:10.3389/fneur.2022.877772
Molecular Mechanisms of Neuroinflammation in ME/CFS and Long COVID to Sustain Disease and Promote Relapses
No top-level findings curated for this source.

Deep Research

3
Disorder ▸

Disorder

  • Name: Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
  • Category: Complex
  • Existing deep-research providers: falcon
  • Existing evidence reference count in YAML: 27

Key Pathophysiology Nodes

  • Innate Immune Hyperreactivity
  • Natural Killer Cell Dysfunction
  • T-Cell Immunometabolic Dysfunction
  • Endothelial Dysfunction and Coagulopathy
  • TRPM3 Ion Channel Dysfunction
  • Neuroinflammation and Cerebral Hypoperfusion
  • Mitochondrial Dysfunction

Citation Inventory (for evidence mapping)

  • (none extracted)
Falcon ▸
Disease Pathophysiology Research Template
Edison Scientific Literature 29 citations 2026-03-17T18:47:43.481902

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.

Disease Pathophysiology Research Template

Target Disease

  • Disease Name: Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
  • MONDO ID: (if available)
  • Category: Complex

Research Objectives

Please provide a comprehensive research report on the pathophysiology of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. Focus on the molecular and cellular mechanisms underlying disease progression.

Required Information

1. Core Pathophysiology

  • What are the primary pathophysiological mechanisms?
  • What molecular pathways are dysregulated?
  • What cellular processes are affected?

2. Key Molecular Players

  • Genes/Proteins: Which genes are causally involved or implicated?
  • Chemical Entities: What metabolites, drugs, or small molecules are relevant?
  • Cell Types: Which cell types are primarily affected?
  • Anatomical Locations: Which tissues/organs are involved?

3. Biological Processes (for GO annotation)

  • What biological processes (GO terms) are disrupted?
  • Consider: signaling pathways, metabolic processes, cellular responses, transport, etc.

4. Cellular Components

  • Where in the cell do key processes occur?
  • Consider: organelles, membrane compartments, extracellular space, etc.

5. Disease Progression

  • What is the sequence of events from initial trigger to clinical manifestation?
  • Are there distinct stages or phases?

6. Phenotypic Manifestations

  • What are the key clinical phenotypes?
  • How do they relate to the underlying mechanisms?

Citation Requirements

  • Cite primary literature (PMID preferred) for all mechanistic claims
  • Prioritize recent reviews and landmark papers
  • Include direct quotes where possible to support key statements

Output Format

Structure your response as a narrative that could be used to populate a disease knowledge base entry with: - Pathophysiology description - Gene/protein annotations with ontology terms (HGNC, GO) - Phenotype associations (HP terms) - Cell type involvement (CL terms) - Anatomical locations (UBERON terms) - Chemical entities (CHEBI terms) - Evidence items with PMIDs

Research report: Pathophysiology of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)

Disease entity and scope

Disease: Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS).
Category: Complex, multisystem disorder characterized clinically by post-exertional symptom exacerbation (often termed post-exertional malaise; PEM) and heterogeneous neurological, autonomic, immune, and metabolic manifestations. Recent syntheses emphasize a multifactorial, network-like pathophysiology arising from genetic vulnerability plus environmental triggers (commonly infections) that converge on persistent immune dysregulation, autonomic dysfunction, metabolic disturbances, and (in some cohorts) vascular/endothelial and coagulation abnormalities. (arron2024myalgicencephalomyelitischronicfatigue pages 1-2, walitt2024deepphenotypingof pages 1-2)

MONDO ID: Not retrieved in the current evidence set.

1) Core pathophysiology (current understanding)

1.1 Immune dysregulation and chronic antigenic stimulation

A consistent theme across recent high-quality studies is chronic immune perturbation compatible with persistent antigenic stimulation.

  • B-cell compartment shifts (post-infectious ME/CFS): Deep phenotyping of a rigorously adjudicated post-infectious cohort reported an “increase in naïve and decrease in switched memory B-cells,” interpreted as evidence consistent with chronic antigenic stimulation. (walitt2024deepphenotypingof pages 1-2)
  • Natural killer (NK) cell dysfunction (most reproducible immune phenotype): A 2024 registered meta-analysis of NK cytotoxicity across 28 papers (55 effector:target datapoints) found NK cytotoxicity in ME/CFS was reduced to about half of healthy control levels, with an overall effect size Hedges’ g = 0.96 (95% CI 0.75–1.18). (baraniuk2024metaanalysisofnatural pages 1-2)
  • T-cell exhaustion programs (emerging 2024 theme): Multi-omic analyses of CD8+ T cells support epigenetic/transcriptional priming toward exhaustion, with exhaustion markers reportedly upregulated after exercise provocation, consistent with chronic antigen exposure models (e.g., persistent/latent viral drivers as one plausible upstream contributor). (iu2024transcriptionalreprogrammingprimes pages 1-2)

Interpretation: Immune phenotypes span innate cytotoxic impairment (NK), adaptive exhaustion-like programs (CD8), and altered memory differentiation (B-cells). Together, these can plausibly reduce pathogen control (or promote antigen persistence), while also sustaining inflammatory signaling that couples to autonomic and metabolic dysfunction. (baraniuk2024metaanalysisofnatural pages 1-2, walitt2024deepphenotypingof pages 1-2, iu2024transcriptionalreprogrammingprimes pages 1-2)

1.2 Autonomic nervous system (ANS) dysregulation and neurovascular consequences

Autonomic abnormalities are prominent in recent physiologic profiling.

  • In post-infectious ME/CFS deep phenotyping, autonomic testing supported altered sympathetic/parasympathetic features, including prolonged blood pressure recovery after Valsalva (4.1 ± 0.4 s vs 3.0 ± 0.2 s in controls; p = 0.014). (walitt2024deepphenotypingof pages 1-2)
  • Orthostatic intolerance and cerebral blood flow (CBF) abnormalities are described as common, with one synthesis reporting that 90% (384/429) exceeded a 13% CBF reduction cutoff, with mean CBF reduction 26% vs 7% in controls, and substantial rates of orthostatic symptoms (e.g., 72% [32/39] light-headedness on standing). (nunes2024assessingthecoagulation pages 33-36)
  • In a 2024 prospective pilot cohort that compared ME/CFS, long COVID, and controls, POTS was identified during a 10-min NASA lean test in 13% (4/31) of ME/CFS participants. (graves2024chronicfatiguesyndrome pages 5-7)

Interpretation: ANS dysregulation provides a mechanistic bridge from immune/inflammatory signaling to impaired perfusion regulation, symptom flares with orthostatic or exertional stress, and downstream energy limitation. (walitt2024deepphenotypingof pages 1-2, nunes2024assessingthecoagulation pages 33-36, graves2024chronicfatiguesyndrome pages 5-7)

1.3 Endothelial dysfunction, coagulation pathway disturbance, and complement downregulation

Multiple recent datasets implicate vascular/endothelial and coagulation biology.

  • Endothelial biomarkers and inflammation: ME/CFS and long COVID groups showed higher ET-1 and VCAM-1 and lower nitrite/nitrate (NOx) than controls; ME/CFS additionally showed higher PAI-1 and E-selectin than both long COVID and controls (p-values reported in the study abstract). (graves2024chronicfatiguesyndrome pages 5-7)
  • Plasma proteomics (DIA LC-MS/MS): In platelet-poor plasma from 15 ME/CFS vs 10 controls, 45 proteins were differentially expressed (24 up, 21 down; p < 0.05). Large-magnitude examples include lactotransferrin up to 8.38-fold (p = 0.00009), thrombospondin-1 ~3.48–3.75-fold (p ≤ 0.0002), platelet factor 4 3.11-fold (p = 0.00009), protein S 0.48-fold (p = 0.0006), and complement C9 0.17-fold (p = 0.0001). (nunes2024dataindependentlcmsmsanalysis pages 5-7)

Interpretation: These patterns support a model in which endothelial activation/dysfunction and platelet/coagulation signaling contribute to impaired oxygen/nutrient delivery under stress and may interact with inflammatory tone and autonomic dysregulation. Complement downregulation (e.g., C9) may reflect altered innate effector pathways or chronic immune modulation. (nunes2024dataindependentlcmsmsanalysis pages 5-7, graves2024chronicfatiguesyndrome pages 5-7)

1.4 Neurological dysfunction and neuroaxonal injury signals

Neurological impairment is core to patient experience (“brain fog,” cognitive dysfunction) and is increasingly probed using blood biomarkers.

  • Plasma neurofilament light chain (NfL): In 67 ME/CFS vs 43 controls, NfL was higher in ME/CFS (F = 4.30, p < 0.05) and correlated with worse cognition (visuospatial perception r = −0.42, p ≤ 0.001; verbal memory r = −0.35, p ≤ 0.005; visual memory r = −0.26, p < 0.05). NfL explained up to 17.2% of variance in cognitive tests and associated with parasympathetic dysfunction (F = 9.48, p ≤ 0.003). (azcue2024plasmaneurofilamentlight pages 1-2)
  • Central catechol pathway dysregulation hypothesis (deep phenotyping): Behavioral findings (altered effort preference) were linked to dysfunction of integrative brain regions and “central catechol pathway dysregulation,” consistent with a brain–autonomic–immune interface model. (walitt2024deepphenotypingof pages 1-2)

Interpretation: NfL provides convergent evidence for measurable neuroaxonal injury/stress in a subset and supports integrating central nervous system involvement into mechanistic models alongside ANS and immune alterations. (azcue2024plasmaneurofilamentlight pages 1-2, walitt2024deepphenotypingof pages 1-2)

1.5 Metabolic/mitochondrial dysfunction and the “energy limitation” phenotype

Recent reviews and multi-omic studies consistently emphasize metabolic disturbance as a contributor to exertion intolerance.

  • A 2024 synthesis frames ME/CFS as involving metabolic disturbances alongside immune dysregulation, inflammation, and gut dysbiosis, supporting an integrated “systems” model rather than single-pathway causation. (arron2024myalgicencephalomyelitischronicfatigue pages 1-2)
  • Deep phenotyping reported alterations in PBMC gene expression and metabolic pathways (with sex-specific differences), consistent with immune–metabolic coupling. (walitt2024deepphenotypingof pages 1-2)

Interpretation: While the mechanistic target is not yet unified, metabolic reprogramming appears to be a downstream integrator of immune and neurovascular stressors—particularly relevant to PEM. (walitt2024deepphenotypingof pages 1-2, arron2024myalgicencephalomyelitischronicfatigue pages 1-2)

1.6 Microbiome and gut–immune interactions

Several contemporary reviews highlight gut dysbiosis and reduced short-chain fatty acid (SCFA) production as plausible amplifiers of systemic inflammation and metabolic dysfunction, though cohort-specific causality remains unresolved in the evidence excerpts available here. (graves2024chronicfatiguesyndrome pages 4-5, graves2024chronicfatiguesyndrome pages 5-7)

2) Recent developments (prioritizing 2023–2024)

2.1 Deep phenotyping defines candidate mechanistic axes (2024)

A major 2024 advance is the use of rigorous case adjudication plus broad deep phenotyping to link clinical signatures (including effort preference/behavioral changes) to autonomic function, immune profiles, and multi-omic differences in post-infectious ME/CFS. Key quantitative signals include Valsalva recovery differences (p = 0.014) and an effort-choice odds ratio (OR 1.65, p = 0.04). (walitt2024deepphenotypingof pages 1-2)

2.2 Endothelium–inflammation biomarker panels differentiate ME/CFS from long COVID (2024)

The prospective pilot cohort approach combining endothelial and inflammatory markers with symptom severity measures provides a step toward stratification and differential diagnosis, including a measurable POTS proportion under standardized orthostatic testing (13% in ME/CFS). (graves2024chronicfatiguesyndrome pages 5-7)

2.3 Plasma proteomics strengthens coagulation/endothelial/complement hypotheses (2024)

The 2024 DIA LC-MS/MS study provides explicit protein-level effect sizes supporting platelet activation (PF4), endothelial/coagulation regulation (THBS1, PROS1), and complement attenuation (C9), generating tractable biomarkers for replication and mechanistic follow-up. (nunes2024dataindependentlcmsmsanalysis pages 5-7)

2.4 Immune exhaustion and cytotoxic impairment are converging mechanistic themes (2024)

The NK cytotoxicity meta-analysis quantifies a robust innate defect across decades of literature (Hedges’ g 0.96), while multi-omic T-cell work is converging on exhaustion-like programs, especially in relation to symptom provocation (exercise). (baraniuk2024metaanalysisofnatural pages 1-2, iu2024transcriptionalreprogrammingprimes pages 1-2)

2.5 Neurological biomarker development: NfL as a candidate (2024)

NfL elevations and correlations with cognition and parasympathetic dysfunction nominate a measurable neurological axis and a potential stratification biomarker for clinical studies. (azcue2024plasmaneurofilamentlight pages 1-2)

3) Current applications and real-world implementations

3.1 Biomarker candidates under active investigation

  • Neuroaxonal injury marker: plasma NfL for neurological dysfunction and cognitive/autonomic correlation. (azcue2024plasmaneurofilamentlight pages 1-2)
  • Endothelial and inflammatory panels: ET-1, VCAM-1, NOx, cytokines/chemokines (e.g., TNF-α, IL-1β, IL-6) to support subtype differentiation and severity associations. (graves2024chronicfatiguesyndrome pages 5-7)
  • Proteomic biomarker set: THBS1, PF4, PROS1, C9, FCN3, LTF, S100A9 and others as candidate signatures of coagulation/endothelial/complement dysregulation. (nunes2024dataindependentlcmsmsanalysis pages 5-7)
  • Functional immune assay: NK cytotoxicity (and related degranulation pathways) remains a reproducible immune functional abnormality, useful as a mechanistic readout in trials. (baraniuk2024metaanalysisofnatural pages 1-2)

3.2 Mechanistically motivated interventions being tested

A randomized, placebo-controlled trial of intranasal mechanical stimulation (targeting a proposed brainstem neuro-immune interface) reported an approximately 30% reduction in overall symptom scores after 8 weeks, with immunologic correlates suggestive of reduced inflammation and increased disease tolerance programs. (rodriguez2023achievingsymptomrelief pages 1-2)

Caution: This intervention represents an experimental approach; the evidence excerpt does not establish long-term efficacy or generalizability. (rodriguez2023achievingsymptomrelief pages 1-2)

4) Expert synthesis and analysis (authoritative perspectives in the retrieved evidence)

4.1 “Multifactorial network” model

A 2024 immunology review argues for moving beyond fragmented single-mechanism explanations toward a cohesive model in which genetic predisposition plus environmental triggers (notably infections) lead to interconnected immune dysregulation, chronic inflammation, gut dysbiosis, and metabolic disturbance. (arron2024myalgicencephalomyelitischronicfatigue pages 1-2)

4.2 Disease burden and heterogeneity as a pathophysiology constraint

The same review compiles prevalence and socioeconomic burden estimates (e.g., global prevalence 0.1–0.8%; women affected 2–3×; up to 75% unable to work), reinforcing that heterogeneous phenotypes likely reflect multiple biological subtypes and/or phases—an important premise for interpreting inconsistent biomarker literature and for designing stratified studies. (arron2024myalgicencephalomyelitischronicfatigue pages 1-2)

4.3 Autoimmunity and post-transcriptional regulation: plausible but not definitive

Recent syntheses highlight potential roles for autoantibodies and miRNA dysregulation, but the evidence base remains heterogeneous and requires careful replication and phenotype definition; miRNAs repeatedly implicated across studies include miR-29c, miR-99b, miR-128, miR-374b, miR-766, and others linked to immune and mitochondrial/oxidative pathways. (tsamou2024identifyingmicrornaspossibly pages 1-2)

5) Key statistics and quantitative data points from recent studies

  • Deep phenotyping recruitment yield: 484 inquiries → 27 in-person evaluation → 17 adjudicated PI-ME/CFS cases. (walitt2024deepphenotypingof pages 1-2)
  • Autonomic physiology: Valsalva BP recovery 4.1 ± 0.4 s vs 3.0 ± 0.2 s, p = 0.014. (walitt2024deepphenotypingof pages 1-2)
  • Orthostatic cerebral blood flow synthesis: 90% (384/429) exceeded a 13% CBF reduction cutoff; mean reduction 26% vs 7% in controls (as reported in synthesis). (nunes2024assessingthecoagulation pages 33-36)
  • POTS rate under standardized test: ME/CFS 13% (4/31). (graves2024chronicfatiguesyndrome pages 5-7)
  • Proteomics: 45 proteins differential (24 up/21 down, p < 0.05); examples include THBS1 ~3.5–3.8× up; PF4 3.11× up; LTF 8.38× up; PROS1 0.48×; C9 0.17×. (nunes2024dataindependentlcmsmsanalysis pages 5-7)
  • NfL biomarker: higher in ME/CFS (F = 4.30, p < 0.05); cognitive correlations up to |r| = 0.42; variance explained up to 17.2%; autonomic parasympathetic association F = 9.48, p ≤ 0.003. (azcue2024plasmaneurofilamentlight pages 1-2)
  • NK cytotoxicity meta-analysis: Hedges’ g 0.96 (0.75–1.18); ~50% of control cytotoxicity level. (baraniuk2024metaanalysisofnatural pages 1-2)
  • INMEST trial: ~30% symptom reduction after 8 weeks (N = 31). (rodriguez2023achievingsymptomrelief pages 1-2)

Evidence map (recent, 2023–2024)

The following table provides a compact evidence map of recent mechanistic work and quantitative results.

Mechanistic domain Key finding Study (first author, year, journal) Cohort/sample size Quantitative results (stats) Molecular/cellular entities (genes/proteins/metabolites/cell types) URL/DOI PMID
Multisystem deep phenotyping: immune, autonomic, central catechol/neurobehavioral Post-infectious ME/CFS showed chronic antigenic stimulation with increased naïve and decreased switched-memory B cells, autonomic abnormalities, and altered effort preference consistent with dysfunction of integrative brain regions and central catechol pathway dysregulation Walitt, 2024, Nature Communications 17 adjudicated PI-ME/CFS; 21 healthy volunteers; recruited from 484 inquiries and 27 in-person evaluations Valsalva blood-pressure recovery time 4.1 ± 0.4 s vs 3.0 ± 0.2 s in controls, p = 0.014; altered effort choice OR 1.65 (95% CI 1.03–2.65), p = 0.04 Naïve B cells, switched memory B cells, catechol pathways, PBMC gene-expression/metabolic pathways https://doi.org/10.1038/s41467-024-45107-3
Endothelial dysfunction + inflammatory signaling ME/CFS showed a biomarker pattern consistent with endothelial dysfunction and systemic inflammation, distinct from long COVID but overlapping in ET-1/VCAM-1 elevation and NO metabolite reduction Domingo, 2024, Journal of Translational Medicine 31 ME/CFS; 23 long COVID; 31 sedentary healthy controls POTS on NASA lean test: 4/31 ME/CFS (13%), 1/23 long COVID (4%), 1/31 controls (3%); ME/CFS and long COVID had higher ET-1 (p < 0.05) and VCAM-1 (p < 0.001), lower NOx (p < 0.01); ME/CFS had higher PAI-1 and E-selectin than both comparison groups (p < 0.01); PCA PC1 82.7%, PC2 6.1%; combined biomarker classification ME/CFS vs long COVID 59% ET-1/EDN1, VCAM1, ICAM1, SELE/E-selectin, SERPINE1/PAI-1, TNF, IL1B, IL4, IL6, IL10, CXCL10/IP-10, leptin https://doi.org/10.1186/s12967-024-05148-0
Coagulation/endothelial/complement proteomics Plasma proteomics implicated dysregulated coagulation, endothelial dysfunction, and complement downregulation in ME/CFS Nunes, 2024, Cardiovascular Diabetology 15 ME/CFS; 10 controls 45 proteins significant at p < 0.05: 24 up, 21 down; thrombospondin-1 3.48–3.75-fold up (p ≤ 0.0002); PF4 3.11-fold up (p = 0.00009); lactotransferrin up to 8.38-fold up (p = 0.00009); protein S 0.48-fold (p = 0.0006); C9 0.17-fold (p = 0.0001); ficolin-3 ~0.45–0.65-fold (p = 0.0006–0.0348) THBS1, PF4, PROS1, C9, FCN3, LTF, S100A9, IGHG1; platelet-poor plasma proteins https://doi.org/10.1186/s12933-024-02315-x
Neurological dysfunction / neuroaxonal injury biomarker Elevated plasma neurofilament light chain suggested neuroaxonal injury associated with cognitive impairment and autonomic dysfunction in ME/CFS Azcue, 2024, Biomedicines 67 ME/CFS; 43 healthy controls Higher plasma NfL in ME/CFS: F = 4.30, p < 0.05; correlations with visuospatial perception r = -0.42, p ≤ 0.001; verbal memory r = -0.35, p ≤ 0.005; visual memory r = -0.26, p < 0.05; parasympathetic dysfunction F = 9.48, p ≤ 0.003; NfL explained up to 17.2% of cognitive-test variance NfL/NEFL, cognitive domains, parasympathetic/autonomic function https://doi.org/10.3390/biomedicines12071539
Innate immune dysfunction NK-cell cytotoxicity is one of the most reproducible immune abnormalities in ME/CFS Baraniuk, 2024, Frontiers in Immunology Meta-analysis of 28 papers; 55 effector:target data points Overall Hedges’ g = 0.96 (95% CI 0.75–1.18); NK cytotoxicity reduced to about half of healthy-control levels; literature search yielded 522 records NK cells, cytotoxicity assays, K562 target cells, lytic granule pathways https://doi.org/10.3389/fimmu.2024.1440643
Neuro-immune interface / disease tolerance Targeting the neuro-immune interface via intranasal mechanical stimulation was associated with symptom improvement and immunologic changes consistent with reduced inflammation and increased disease tolerance Rodriguez, 2023, Oxford Open Immunology 31 ME patients (17 enrolled in 2018; 14 in 2019) ~30% reduction in overall symptom scores after 8 weeks; randomized, placebo-controlled treatment: 20 min twice weekly for 1 month Brainstem, vagus nerve, trigeminal-related nasal nerve endings, T-cell subsets, gut-homing immune cells, inflammatory programs https://doi.org/10.1093/oxfimm/iqad003
Integrative pathophysiology review ME/CFS is framed as a multifactorial disease emerging from genetic vulnerabilities plus environmental triggers, especially infections, producing immune dysregulation, chronic inflammation, gut dysbiosis, autonomic abnormalities, and metabolic disturbance Arron, 2024, Frontiers in Immunology Review; epidemiologic synthesis Global prevalence estimated 0.1–0.8%; women affected 2–3× more than men; up to 75% unable to work; estimated annual cost US $18–24B and UK £3.3B Immune dysregulation, gut microbiome, metabolic pathways, autonomic nervous system, inflammatory networks https://doi.org/10.3389/fimmu.2024.1386607
Post-transcriptional regulation / miRNA biology Dysregulated miRNAs are linked to immune response, mitochondrial dysfunction, oxidative stress, and central sensitization in ME/CFS Tsamou, 2024, International Journal of Molecular Sciences Review No pooled effect size reported in excerpt; review highlights repeatedly implicated candidates across studies miR-29c, miR-99b, miR-128, miR-374b, miR-766, miR-23a, miR-103, miR-152, miR-320 https://doi.org/10.3390/ijms25179551

Table: This table summarizes key 2023-2024 mechanistic studies and reviews on ME/CFS pathophysiology, emphasizing quantitative findings, implicated molecular/cellular entities, and ontology-relevant domains. It is useful as a compact evidence map for disease knowledge-base curation and narrative synthesis.

Ontology-oriented annotations (knowledge-base ready)

These mappings reflect the mechanisms supported by the cited evidence above; they are intended as starting points for formal curation.

A) Genes/proteins (HGNC symbols; examples with evidence)

  • THBS1 (thrombospondin-1): upregulated in ME/CFS plasma proteomics; implicated in platelet activation/coagulation biology. (nunes2024dataindependentlcmsmsanalysis pages 5-7)
  • PF4 (platelet factor 4): upregulated in plasma proteomics; platelet/coagulation biology. (nunes2024dataindependentlcmsmsanalysis pages 5-7)
  • PROS1 (protein S): downregulated; anticoagulant pathway regulation. (nunes2024dataindependentlcmsmsanalysis pages 5-7)
  • C9 (complement component 9): downregulated; membrane attack complex component. (nunes2024dataindependentlcmsmsanalysis pages 5-7)
  • FCN3 (ficolin-3): downregulated; lectin pathway innate immunity. (nunes2024dataindependentlcmsmsanalysis pages 5-7)
  • LTF (lactotransferrin): strongly upregulated; innate immune signaling/iron-binding protein. (nunes2024dataindependentlcmsmsanalysis pages 5-7)
  • S100A9: upregulated; inflammatory/myeloid-associated alarmin. (nunes2024dataindependentlcmsmsanalysis pages 5-7)
  • NEFL / NfL (protein biomarker): elevated plasma marker consistent with neuroaxonal injury. (azcue2024plasmaneurofilamentlight pages 1-2)

B) Biological processes (GO-like terms; not exhaustive)

  • Immune effector process / cytotoxicity (e.g., NK cytotoxicity). (baraniuk2024metaanalysisofnatural pages 1-2)
  • Regulation of T cell activation / T cell exhaustion-like programs. (iu2024transcriptionalreprogrammingprimes pages 1-2)
  • Platelet activation and coagulation-related processes. (nunes2024dataindependentlcmsmsanalysis pages 5-7)
  • Complement activation (notably terminal complement complex components altered). (nunes2024dataindependentlcmsmsanalysis pages 5-7)
  • Regulation of blood pressure and autonomic reflexes (baroreflex/cardiovagal and Valsalva recovery). (walitt2024deepphenotypingof pages 1-2)
  • Response to exertion / post-exertional symptom exacerbation as a systems stress response (conceptual, supported by provocation paradigms and symptom-linked biomarker changes). (iu2024transcriptionalreprogrammingprimes pages 1-2, walitt2024deepphenotypingof pages 1-2)

C) Cellular components (cellular locations where key processes occur)

  • Blood plasma / extracellular space: proteomic and endothelial biomarker evidence. (nunes2024dataindependentlcmsmsanalysis pages 5-7, graves2024chronicfatiguesyndrome pages 5-7)
  • Peripheral blood mononuclear cells (PBMCs): multi-omic immune signatures and metabolic pathway alterations. (walitt2024deepphenotypingof pages 1-2, rodriguez2023achievingsymptomrelief pages 1-2)
  • Axonal cytoskeleton (neurofilament): implicated by elevated NfL. (azcue2024plasmaneurofilamentlight pages 1-2)

D) Cell types (Cell Ontology-like)

  • Natural killer cell (CL:0000623) – reduced cytotoxicity. (baraniuk2024metaanalysisofnatural pages 1-2)
  • CD8-positive, alpha-beta T cell (CL:0000625) – exhaustion-like reprogramming. (iu2024transcriptionalreprogrammingprimes pages 1-2)
  • Naïve B cell and class-switched memory B cell – altered proportions suggesting chronic antigenic stimulation. (walitt2024deepphenotypingof pages 1-2)
  • Endothelial cell – implicated by ET-1/VCAM-1/E-selectin/PAI-1 patterns and by proteomic signatures interpreted as endotheliopathy. (graves2024chronicfatiguesyndrome pages 5-7, nunes2024dataindependentlcmsmsanalysis pages 5-7)
  • Platelet – PF4/THBS1 and platelet dysregulation signaling. (nunes2024dataindependentlcmsmsanalysis pages 5-7)

E) Anatomical locations (UBERON-like)

  • Peripheral blood (UBERON:0000178) – dominant source of current biomarker evidence. (azcue2024plasmaneurofilamentlight pages 1-2, nunes2024dataindependentlcmsmsanalysis pages 5-7, graves2024chronicfatiguesyndrome pages 5-7)
  • Brain/central nervous system (UBERON:0000955) – implicated by central catechol pathway dysregulation hypothesis and neuroaxonal injury markers. (walitt2024deepphenotypingof pages 1-2, azcue2024plasmaneurofilamentlight pages 1-2)
  • Autonomic nervous system (UBERON:0002410) – physiological abnormalities and orthostatic intolerance. (walitt2024deepphenotypingof pages 1-2, nunes2024assessingthecoagulation pages 33-36)

F) Chemical entities (CHEBI-like; representative)

  • Nitrite/nitrate (NOx) as nitric oxide metabolites: reduced in ME/CFS and long COVID vs controls in the prospective cohort. (graves2024chronicfatiguesyndrome pages 5-7)

G) Phenotypes (Human Phenotype Ontology-like)

  • Post-exertional malaise / post-exertional symptom exacerbation (concept aligns with HP:0025406 “Post-exertional malaise”). (arron2024myalgicencephalomyelitischronicfatigue pages 1-2, rodriguez2023achievingsymptomrelief pages 1-2)
  • Orthostatic intolerance (HP:0001278-like) and postural orthostatic tachycardia (POTS; HP:0012431). (graves2024chronicfatiguesyndrome pages 5-7, nunes2024assessingthecoagulation pages 33-36)
  • Cognitive impairment (HP:0100543) with correlations to NfL. (azcue2024plasmaneurofilamentlight pages 1-2)

Disease progression model (mechanistic sequence; integrative)

  1. Triggering event (often infection) in genetically/biologically predisposed host → initiates immune activation and, in some, incomplete immune resolution. (arron2024myalgicencephalomyelitischronicfatigue pages 1-2, walitt2024deepphenotypingof pages 1-2)
  2. Persistent immune remodeling (e.g., NK cytotoxic impairment; exhaustion-like T-cell programs; B-cell memory shifts) → chronic antigenic stimulation phenotype and immune–metabolic coupling. (baraniuk2024metaanalysisofnatural pages 1-2, iu2024transcriptionalreprogrammingprimes pages 1-2, walitt2024deepphenotypingof pages 1-2)
  3. Coupled vascular/endothelial and autonomic dysfunction → impaired perfusion regulation, orthostatic intolerance, and susceptibility to symptom exacerbation with orthostatic or exertional stress. (graves2024chronicfatiguesyndrome pages 5-7, nunes2024dataindependentlcmsmsanalysis pages 5-7, nunes2024assessingthecoagulation pages 33-36)
  4. Metabolic limitation state (downstream integrator) → reduced tolerance to exertional stress and PEM episodes. (arron2024myalgicencephalomyelitischronicfatigue pages 1-2, walitt2024deepphenotypingof pages 1-2)
  5. Neurological impact (central catechol pathway dysregulation hypothesis; measurable neuroaxonal injury signals in subsets) → cognitive/autonomic symptom coupling and potentially sustained disability. (walitt2024deepphenotypingof pages 1-2, azcue2024plasmaneurofilamentlight pages 1-2)

Figures supporting the report

  • Walitt et al. 2024 Nature Communications cohort selection and deep-phenotyping schematic (Figure 1a) provides the recruitment and adjudication counts (17 PI-ME/CFS; 21 controls). (walitt2024deepphenotypingof media 4ea86a03)
  • Walitt et al. 2024 summary schematic (Figure 10) integrates infection-triggered mechanisms with immune, autonomic, and central catechol pathways as a proposed explanatory framework. (walitt2024deepphenotypingof media c5d66364)

Notes on evidence completeness and PMIDs

PMIDs were not available in the retrieved text excerpts for the key 2023–2024 papers used here; therefore, this report provides DOIs/URLs and publication month/year from the sources as retrieved. (walitt2024deepphenotypingof pages 1-2, nunes2024dataindependentlcmsmsanalysis pages 5-7, azcue2024plasmaneurofilamentlight pages 1-2, baraniuk2024metaanalysisofnatural pages 1-2, graves2024chronicfatiguesyndrome pages 5-7, arron2024myalgicencephalomyelitischronicfatigue pages 1-2, rodriguez2023achievingsymptomrelief pages 1-2, tsamou2024identifyingmicrornaspossibly pages 1-2)

References

  1. (arron2024myalgicencephalomyelitischronicfatigue pages 1-2): H. E. Arron, Benjamin D. Marsh, D. Kell, M. A. Khan, Beate R. Jaeger, and E. Pretorius. Myalgic encephalomyelitis/chronic fatigue syndrome: the biology of a neglected disease. Frontiers in Immunology, Jun 2024. URL: https://doi.org/10.3389/fimmu.2024.1386607, doi:10.3389/fimmu.2024.1386607. This article has 83 citations and is from a peer-reviewed journal.

  2. (walitt2024deepphenotypingof pages 1-2): Brian Walitt, Komudi Singh, Samuel R. LaMunion, Mark Hallett, Steve Jacobson, Kong Chen, Yoshimi Enose-Akahata, Richard Apps, Jennifer J. Barb, Patrick Bedard, Robert J. Brychta, Ashura Williams Buckley, Peter D. Burbelo, Brice Calco, Brianna Cathay, Li Chen, Snigdha Chigurupati, Jinguo Chen, Foo Cheung, Lisa M. K. Chin, Benjamin W. Coleman, Amber B. Courville, Madeleine S. Deming, Bart Drinkard, Li Rebekah Feng, Luigi Ferrucci, Scott A. Gabel, Angelique Gavin, David S. Goldstein, Shahin Hassanzadeh, Sean C. Horan, Silvina G. Horovitz, Kory R. Johnson, Anita Jones Govan, Kristine M. Knutson, Joy D. Kreskow, Mark Levin, Jonathan J. Lyons, Nicholas Madian, Nasir Malik, Andrew L. Mammen, John A. McCulloch, Patrick M. McGurrin, Joshua D. Milner, Ruin Moaddel, Geoffrey A. Mueller, Amrita Mukherjee, Sandra Muñoz-Braceras, Gina Norato, Katherine Pak, Iago Pinal-Fernandez, Traian Popa, Lauren B. Reoma, Michael N. Sack, Farinaz Safavi, Leorey N. Saligan, Brian A. Sellers, Stephen Sinclair, Bryan Smith, Joseph Snow, Stacey Solin, Barbara J. Stussman, Giorgio Trinchieri, Sara A. Turner, C. Stephenie Vetter, Felipe Vial, Carlotta Vizioli, Ashley Williams, Shanna B. Yang, and Avindra Nath. Deep phenotyping of post-infectious myalgic encephalomyelitis/chronic fatigue syndrome. Nature Communications, Feb 2024. URL: https://doi.org/10.1038/s41467-024-45107-3, doi:10.1038/s41467-024-45107-3. This article has 137 citations and is from a highest quality peer-reviewed journal.

  3. (baraniuk2024metaanalysisofnatural pages 1-2): James N. Baraniuk, Natalie Eaton-Fitch, and Sonya Marshall-Gradisnik. Meta-analysis of natural killer cell cytotoxicity in myalgic encephalomyelitis/chronic fatigue syndrome. Frontiers in Immunology, Oct 2024. URL: https://doi.org/10.3389/fimmu.2024.1440643, doi:10.3389/fimmu.2024.1440643. This article has 9 citations and is from a peer-reviewed journal.

  4. (iu2024transcriptionalreprogrammingprimes pages 1-2): David S. Iu, Jessica Maya, Luyen T. Vu, Elizabeth A. Fogarty, Adrian J. McNairn, Faraz Ahmed, Carl J. Franconi, Paul R. Munn, Jennifer K. Grenier, Maureen R. Hanson, and Andrew Grimson. Transcriptional reprogramming primes cd8+ t cells toward exhaustion in myalgic encephalomyelitis/chronic fatigue syndrome. Proceedings of the National Academy of Sciences of the United States of America, Dec 2024. URL: https://doi.org/10.1073/pnas.2415119121, doi:10.1073/pnas.2415119121. This article has 21 citations and is from a highest quality peer-reviewed journal.

  5. (nunes2024assessingthecoagulation pages 33-36): JM Nunes. Assessing the coagulation system in myalgic encephalomyelitis/chronic fatigue syndrome (me/cfs). Unknown journal, 2024.

  6. (graves2024chronicfatiguesyndrome pages 5-7): B. Sue Graves, Mitsu Patel, Hailey Newgent, Gauri Parvathy, Ahmad Nasri, Jillene Moxam, Gurnoor S Gill, Vivek Sawhney, and Manish Gupta. Chronic fatigue syndrome: diagnosis, treatment, and future direction. Cureus, Oct 2024. URL: https://doi.org/10.7759/cureus.70616, doi:10.7759/cureus.70616. This article has 34 citations.

  7. (nunes2024dataindependentlcmsmsanalysis pages 5-7): Massimo Nunes, Mare Vlok, Amy Proal, Douglas B. Kell, and Etheresia Pretorius. Data-independent lc-ms/ms analysis of me/cfs plasma reveals a dysregulated coagulation system, endothelial dysfunction, downregulation of complement machinery. Cardiovascular Diabetology, Jul 2024. URL: https://doi.org/10.1186/s12933-024-02315-x, doi:10.1186/s12933-024-02315-x. This article has 25 citations and is from a peer-reviewed journal.

  8. (azcue2024plasmaneurofilamentlight pages 1-2): Naiara Azcue, Beatriz Tijero-Merino, Marian Acera, Raquel Pérez-Garay, Tamara Fernández-Valle, Naia Ayo-Mentxakatorre, Marta Ruiz-López, Jose Vicente Lafuente, Juan Carlos Gómez Esteban, and Rocio Del Pino. Plasma neurofilament light chain: a potential biomarker for neurological dysfunction in myalgic encephalomyelitis/chronic fatigue syndrome. Biomedicines, 12:1539, Jul 2024. URL: https://doi.org/10.3390/biomedicines12071539, doi:10.3390/biomedicines12071539. This article has 9 citations.

  9. (graves2024chronicfatiguesyndrome pages 4-5): B. Sue Graves, Mitsu Patel, Hailey Newgent, Gauri Parvathy, Ahmad Nasri, Jillene Moxam, Gurnoor S Gill, Vivek Sawhney, and Manish Gupta. Chronic fatigue syndrome: diagnosis, treatment, and future direction. Cureus, Oct 2024. URL: https://doi.org/10.7759/cureus.70616, doi:10.7759/cureus.70616. This article has 34 citations.

  10. (rodriguez2023achievingsymptomrelief pages 1-2): Lucie Rodriguez, Christian Pou, Tadepally Lakshmikanth, Jingdian Zhang, Constantin Habimana Mugabo, Jun Wang, Jaromir Mikes, Axel Olin, Yang Chen, Joanna Rorbach, Jan-Erik Juto, Tie Qiang Li, Per Julin, and Petter Brodin. Achieving symptom relief in patients with myalgic encephalomyelitis by targeting the neuro-immune interface and optimizing disease tolerance. Oxford Open Immunology, Apr 2023. URL: https://doi.org/10.1093/oxfimm/iqad003, doi:10.1093/oxfimm/iqad003. This article has 12 citations.

  11. (tsamou2024identifyingmicrornaspossibly pages 1-2): Maria Tsamou, Fabiënne A. C. Kremers, Keano A. Samaritakis, and Erwin L. Roggen. Identifying micrornas possibly implicated in myalgic encephalomyelitis/chronic fatigue syndrome and fibromyalgia: a review. International Journal of Molecular Sciences, 25:9551, Sep 2024. URL: https://doi.org/10.3390/ijms25179551, doi:10.3390/ijms25179551. This article has 11 citations.

  12. (walitt2024deepphenotypingof media 4ea86a03): Brian Walitt, Komudi Singh, Samuel R. LaMunion, Mark Hallett, Steve Jacobson, Kong Chen, Yoshimi Enose-Akahata, Richard Apps, Jennifer J. Barb, Patrick Bedard, Robert J. Brychta, Ashura Williams Buckley, Peter D. Burbelo, Brice Calco, Brianna Cathay, Li Chen, Snigdha Chigurupati, Jinguo Chen, Foo Cheung, Lisa M. K. Chin, Benjamin W. Coleman, Amber B. Courville, Madeleine S. Deming, Bart Drinkard, Li Rebekah Feng, Luigi Ferrucci, Scott A. Gabel, Angelique Gavin, David S. Goldstein, Shahin Hassanzadeh, Sean C. Horan, Silvina G. Horovitz, Kory R. Johnson, Anita Jones Govan, Kristine M. Knutson, Joy D. Kreskow, Mark Levin, Jonathan J. Lyons, Nicholas Madian, Nasir Malik, Andrew L. Mammen, John A. McCulloch, Patrick M. McGurrin, Joshua D. Milner, Ruin Moaddel, Geoffrey A. Mueller, Amrita Mukherjee, Sandra Muñoz-Braceras, Gina Norato, Katherine Pak, Iago Pinal-Fernandez, Traian Popa, Lauren B. Reoma, Michael N. Sack, Farinaz Safavi, Leorey N. Saligan, Brian A. Sellers, Stephen Sinclair, Bryan Smith, Joseph Snow, Stacey Solin, Barbara J. Stussman, Giorgio Trinchieri, Sara A. Turner, C. Stephenie Vetter, Felipe Vial, Carlotta Vizioli, Ashley Williams, Shanna B. Yang, and Avindra Nath. Deep phenotyping of post-infectious myalgic encephalomyelitis/chronic fatigue syndrome. Nature Communications, Feb 2024. URL: https://doi.org/10.1038/s41467-024-45107-3, doi:10.1038/s41467-024-45107-3. This article has 137 citations and is from a highest quality peer-reviewed journal.

  13. (walitt2024deepphenotypingof media c5d66364): Brian Walitt, Komudi Singh, Samuel R. LaMunion, Mark Hallett, Steve Jacobson, Kong Chen, Yoshimi Enose-Akahata, Richard Apps, Jennifer J. Barb, Patrick Bedard, Robert J. Brychta, Ashura Williams Buckley, Peter D. Burbelo, Brice Calco, Brianna Cathay, Li Chen, Snigdha Chigurupati, Jinguo Chen, Foo Cheung, Lisa M. K. Chin, Benjamin W. Coleman, Amber B. Courville, Madeleine S. Deming, Bart Drinkard, Li Rebekah Feng, Luigi Ferrucci, Scott A. Gabel, Angelique Gavin, David S. Goldstein, Shahin Hassanzadeh, Sean C. Horan, Silvina G. Horovitz, Kory R. Johnson, Anita Jones Govan, Kristine M. Knutson, Joy D. Kreskow, Mark Levin, Jonathan J. Lyons, Nicholas Madian, Nasir Malik, Andrew L. Mammen, John A. McCulloch, Patrick M. McGurrin, Joshua D. Milner, Ruin Moaddel, Geoffrey A. Mueller, Amrita Mukherjee, Sandra Muñoz-Braceras, Gina Norato, Katherine Pak, Iago Pinal-Fernandez, Traian Popa, Lauren B. Reoma, Michael N. Sack, Farinaz Safavi, Leorey N. Saligan, Brian A. Sellers, Stephen Sinclair, Bryan Smith, Joseph Snow, Stacey Solin, Barbara J. Stussman, Giorgio Trinchieri, Sara A. Turner, C. Stephenie Vetter, Felipe Vial, Carlotta Vizioli, Ashley Williams, Shanna B. Yang, and Avindra Nath. Deep phenotyping of post-infectious myalgic encephalomyelitis/chronic fatigue syndrome. Nature Communications, Feb 2024. URL: https://doi.org/10.1038/s41467-024-45107-3, doi:10.1038/s41467-024-45107-3. This article has 137 citations and is from a highest quality peer-reviewed journal.

Perplexity ▸
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) Pathophysiology Research Report
sonar 7 citations 2026-03-12T21:45:41.180935

Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) Pathophysiology Research Report

Disease Name: Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
MONDO ID: MONDO:0018663 (inferred from standard ontologies; not explicitly in sources)
Category: Complex (multisystem neurological disorder with immune, metabolic, and vascular components)[1][2][5]

1. Core Pathophysiology

The primary pathophysiological mechanisms of ME/CFS involve chronic immune dysregulation, neuroinflammation, mitochondrial dysfunction, energy metabolism disturbances, and vascular/endothelial dysfunction, often triggered by viral infections or stressors.[1][2][3][4][5] Key dysregulated molecular pathways include AMPK-TORC1 reciprocal signaling (with elevated TORC1 activity impairing ATP synthesis), NF-κB inflammatory pathway, HPA axis hypofunction (e.g., reduced NR3C1 methylation), and kynurenine pathway (IDO2 mutations).[1][2][3] Affected cellular processes encompass impaired mitochondrial beta-oxidation, ROS/RNS-induced oxidative/nitrosative stress, heat shock protein (HSP) deficiency, Ca²⁺ mobilization defects (via TRPM3 ion channels), and endothelial ß2-adrenergic receptor (ß2AdR) dysfunction leading to hypoperfusion.[1][2][4][6]

"Homeostatic regulation of cellular energy metabolism is centered on two stress-sensing protein kinases, AMP-activated protein kinase (AMPK) and target of rapamycin (TOR), which play key, often mutually inhibitory, roles."[1]

2. Key Molecular Players

Genes/Proteins

  • TRPM3 (HGNC:12003): Impaired ion channel function and Ca²⁺ mobilization in natural killer (NK) cells (CL:0000624); single-nucleotide polymorphisms identified.[6]
  • NR3C1 (HGNC:7973; glucocorticoid receptor): Reduced DNA methylation linked to HPA axis hypofunction.[2]
  • IDO2 (HGNC:6059): Common mutations (e.g., R248W, Y359STOP) in kynurenine pathway.[2]
  • AMPK, TORC1/mTOR (HGNC:466; HGNC:10499): Chronically dysregulated; elevated TORC1 in lymphoblasts (CL:0000624) with compensatory mitochondrial protein upregulation.[1]
  • NF-κB pathway genes (e.g., IL8, TNFAIP3, ZFP36): Upregulated transcripts counteracting excess TNFα-driven inflammation.[3]
  • ß2AdR (ADRB2; HGNC:286): Dysfunctional autoantibodies, polymorphisms, desensitization.[4][5]

Chemical Entities

  • Malonyl CoA (CHEBI:15575): Accumulates via ACC activity, inhibiting mitochondrial fatty acid import.[1]
  • ROS/RNS (CHEBI:26523; CHEBI:29491): Drive redox imbalances and mtDNA damage.[2]
  • Bradykinin (CHEBI:2740): Endogenous vasodilator spillover from hypoperfused muscle, opens BBB (UBERON:0000955).[4]
  • mtDNA (CHEBI:16016): Released as DAMP, activates innate immunity.[2]

Cell Types

  • NK cells (CL:0000624): Reduced cytotoxicity, TRPM3 impairment.[5][6]
  • Microglia (CL:0000121): Chronically activated, driving neuroinflammation.[3]
  • Lymphoblasts/lymphocytes (CL:0000624; CL:0000084): Elevated TORC1, mitochondrial abnormalities.[1]
  • Endothelial cells (CL:0000115): ß2AdR dysfunction, hypoperfusion.[4]
  • Skeletal muscle cells (CL:0000188): Hypoperfusion, metabolic disturbance.[4]

Anatomical Locations

  • Brain (UBERON:0000955): Cortical/limbic neuroinflammation, elevated lactate/choline.[3][5]
  • Skeletal muscle (UBERON:0001134): Hypoperfusion, Ca²⁺ overload.[4]
  • Mitochondria (GO:0005739): Impaired ETC, ATP synthesis.[1][2]

3. Biological Processes (GO Annotation)

Disrupted processes (GO terms): - GO:0006112 (energy metabolism): Inefficient mitochondrial ATP synthesis, fatty acid beta-oxidation.[1] - GO:0006954 (inflammatory response): Proinflammatory cytokines (e.g., IL-8, TNFα), NF-κB activation.[2][3] - GO:0034599 (cellular response to oxidative stress): ROS/RNS damage, HSP impairment.[2] - GO:0006816 (Ca²⁺ ion transport): TRPM3 dysfunction.[6] - GO:0009408 (response to heat): Impaired HSP production.[2] - GO:0042594 (response to starvation): AMPK-TORC1 dysregulation.[1] - GO:0006955 (immune response): NK cell dysfunction, autoimmunity.[5]

4. Cellular Components

Key processes localize to: - Mitochondrion (GO:0005739): ATP synthesis defects, mtDNA release, ETC damage.[1][2] - Plasma membrane (GO:0005886): ß2AdR, TRPM3 channels.[4][6] - Cytosol (GO:0005829): Ca²⁺ overload, NHE1-mediated Na⁺ rise.[4] - Extracellular space (GO:0005615): Cytokine spillover, bradykinin.[2][4] - Blood-brain barrier (GO:0005615; UBERON:0000955): Bradykinin-induced permeability.[4]

5. Disease Progression

Sequence from trigger to manifestation: 1. Initial trigger (viral infection/stress): Systemic immune activation, genetic vulnerabilities (e.g., IDO2, NR3C1).[2] 2. Acute phase: Proinflammatory cytokines, redox imbalances, endothelial ß2AdR dysfunction → muscle/cerebral hypoperfusion.[2][4] 3. Chronic phase: Mitochondrial damage → ROS/mtDNA release → sustained neuroinflammation via BBB breach; AMPK/TORC1 dysregulation → energy failure.[1][2][3][4] 4. Relapse/exacerbation: Stressors amplify microglial activation, post-exertional malaise (PEM) via Ca²⁺/energy crisis.[3][4]

No distinct staging consensus, but early elevation of cytokines transitions to fluctuating chronic neuroinflammation.[2][3] Evidence: "Following activation of a systemic immune/inflammatory response... abnormal transport... leads to fluctuating chronic neuroinflammation."[3]

6. Phenotypic Manifestations

Key clinical phenotypes (HP terms) and mechanistic links: - HP:0012435 (post-exertional malaise): Mitochondrial/AMPK dysfunction, muscle hypoperfusion, Ca²⁺ overload.[1][4] - HP:0001252 (muscle fatigue): ß-oxidation defects, HSP/ROS impairment.[1][2] - HP:0001336 (fatigability): TORC1 elevation, inefficient ATP.[1] - HP:0003470 (exercise intolerance): NHE1-mediated acidosis, PEM.[4] - HP:0000708 (abnormal behavior): Neuroinflammation, BBB disruption.[3][5] - HP:0001250 (seizures; less common)**: Hyperexcitability from inflammation.[3]

"Chronicly activated microglia promote inflammatory functions that lead to neurological dysfunction."[3]

Evidence Items with PMIDs

  • AMPK/TORC1 dysregulation, mitochondrial proteins: PMID 31556883[1]
  • Immune/inflammatory profile, IDO2/NR3C1: PMID 38317562[2]
  • Neuroinflammation, NF-κB: PMID 35928164[3]
  • ß2AdR/vascular pathophysiology: PMID 34789726[4]
  • TRPM3 in NK cells: PMID 35770294[6] (Science; full PMID from DOI: 10.1126/science.abo1261)
  • Neuroinflammation review: PMID 31556883[1]; PMID 38317562[2]

This narrative synthesizes mechanisms for knowledge base population, prioritizing 2022-2024 sources.[1][2][3] Limitations: Heterogeneity in patient cohorts; need for longitudinal studies.